[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 195
1. Meyer JJ, Willett CG, Czito BG: Emerging role of intensity-modulated radiation therapy in anorectal cancer. Expert Rev Anticancer Ther; 2008 Apr;8(4):585-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although radiation therapy has an established role to play in the management of rectal and anal tumors, there are often treatment-related morbidities that negatively impact on patients.
  • It has been implemented in the treatment of prostate and head and neck tumors with success.
  • This article reviews the rationale for its use in treating anorectal tumors and discusses early clinical data supporting its continued investigation.
  • [MeSH-major] Anus Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18402525.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 58
  •  go-up   go-down


2. Wang H, Fu CG, Zheng JM, Gong HF, Tao LY, Yu ED, Zhang W, Liu LJ, Hao LQ, Meng RG: [Impact of meticulousness of pathologists on lymph node harvest after radical resection of invasive rectal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Nov;12(6):569-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Excluded criteria were recurrent colorectal tumor, Tis tumor, R(1) or R(2) resection, tumor resection transanally or endoscopically, the cases enrolled in other prospective research, synchronous diseases affecting the surgical procedure for the rectal cancer (familial adenomatous polyposis, synchronous colorectal carcinoma) and rectal cancer receiving neoadjuvant chemoradiation.
  • There were no significant differences in gender (46/76 vs 86/156, P=0.436), age (58.1+/-1.3 vs 59.2+/-1.1, P=0.527), distance from tumor to anal verge (7.4+/-0.4 vs 7.1+/-0.3, P=0.761), proportion of sphincter-sparing surgery (67/76 vs 140/156, P=0.715), ratio of well and moderate differentiated tumors (68/76 vs 125/156, P=0.074) and overall TNM stage (P=0.167) between the two groups.
  • [MeSH-major] Biopsy. Lymph Node Excision. Lymph Nodes / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Period. Rectum / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19921565.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


3. Yang JY, Yang MQ, Luo Z, Ma Y, Li J, Deng Y, Huang X: A hybrid machine learning-based method for classifying the Cushing's Syndrome with comorbid adrenocortical lesions. BMC Genomics; 2008;9 Suppl 1:S23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The prognosis for many cancers could be improved dramatically if they could be detected while still at the microscopic disease stage.
  • Because more than one marker must be considered to obtain a classification of cancer or no cancer, and if cancer, to classify it as malignant, borderline, or benign, we must develop an intelligent decision system that can fullfill such an unmet medical need.
  • We have also used immunohistochemistry techniques to measure the gene expression profiles from a number of antigens such as cyclin E, P27KIP1, FHIT, Ki-67, PCNA, Bax, Bcl-2, P53, Fas, FasL and hTERT in several particular types of neuroendocrine tumors such as pheochromocytomas, paragangliomas, and the adrenocortical carcinomas (ACC), adenomas (ACA), and hyperplasia (ACH) involved with Cushing's syndrome.
  • We provided statistical evidence that higher expression levels of hTERT, PCNA and Ki-67 etc. are associated with a higher risk that the tumors are malignant or borderline as opposed to benign.
  • We also investigated whether higher expression levels of P27KIP1 and FHIT, etc., are associated with a decreased risk of adrenomedullary tumors.
  • While no significant difference was found between cell-arrest antigens such as P27KIP1 for malignant, borderline, and benign tumors, there was a significant difference between expression levels of such antigens in normal adrenal medulla samples and in adrenomedullary tumors.
  • This research has many potential applications; it might provide an alternative diagnostic tool and a better understanding of the mechanisms involved in malignant transformation as well as information that is useful for treatment planning and cancer prevention.
  • [MeSH-major] Adrenal Cortex Neoplasms / classification. Algorithms. Artificial Intelligence. Biomarkers, Tumor / metabolism. Cushing Syndrome / classification


Advertisement
4. Venkatesh SK, Yin M, Glockner JF, Takahashi N, Araoz PA, Talwalkar JA, Ehman RL: MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol; 2008 Jun;190(6):1534-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR elastography of liver tumors: preliminary results.
  • OBJECTIVE: The purpose of this study was to evaluate the potential value of MR elastography (MRE) in the characterization of solid liver tumors.
  • MATERIALS AND METHODS: Forty-four liver tumors (14 metastatic lesions, 12 hepatocellular carcinomas, nine hemangiomas, five cholangiocarcinomas, three cases of focal nodular hyperplasia, and one hepatic adenoma) were evaluated with MRE.
  • The tumors were identified on T2- and T1-weighted and gadolinium-enhanced T1-weighted images, and the MRE images were obtained through the tumor.
  • The mean shear stiffness of the tumor was calculated with a manually specified region of interest over the tumor in the stiffness map.
  • The stiffness value of tumor-free hepatic parenchyma was calculated.
  • Statistical analysis was performed on the stiffness values for differentiation of normal liver, fibrotic liver, benign tumors, and malignant tumors.
  • RESULTS: Malignant liver tumors had significantly greater mean shear stiffness than benign tumors (10.1 kPa vs 2.7 kPa, p < 0.001), fibrotic liver (10.1 kPa vs 5.9 kPa, p < 0.001), and normal liver (10.1 kPa vs 2.3 kPa, p < 0.001).
  • Fibrotic livers had stiffness values overlapping both the benign and the malignant tumors.
  • A cutoff value of 5 kPa accurately differentiated malignant tumors from benign tumors and normal liver parenchyma in this preliminary investigation.
  • CONCLUSION: MR elastography is a promising noninvasive technique for assessing solid liver tumors.
  • Use of MRE may lead to new quantitative tissue characterization parameters for differentiating benign and malignant liver tumors.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2001 Jul;14(1):63-71 [11436216.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1207-1213.e2 [17916548.001]
  • [Cites] Med Image Anal. 2001 Dec;5(4):237-54 [11731304.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jun;178(6):1411-7 [12034608.001]
  • [Cites] Clin Radiol. 2002 Nov;57(11):1014-20 [12409113.001]
  • [Cites] Nat Cell Biol. 2003 Sep;5(9):803-11 [12942086.001]
  • [Cites] Med Image Anal. 2003 Dec;7(4):465-73 [14561551.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):695 [14973470.001]
  • [Cites] Ultrason Imaging. 1991 Apr;13(2):111-34 [1858217.001]
  • [Cites] Science. 1995 Sep 29;269(5232):1854-7 [7569924.001]
  • [Cites] Radiology. 1996 Mar;198(3):920-6 [8628896.001]
  • [Cites] Nat Med. 1996 May;2(5):601-3 [8616724.001]
  • [Cites] Radiology. 1997 Jan;202(1):79-86 [8988195.001]
  • [Cites] Magn Reson Imaging. 2005 Feb;23(2):159-65 [15833607.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):325-42 [15838603.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):241-54 [16169468.001]
  • [Cites] Radiology. 2005 Oct;237(1):202-11 [16118150.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] NMR Biomed. 2006 Apr;19(2):173-9 [16521091.001]
  • [Cites] Radiology. 2006 Aug;240(2):440-8 [16864671.001]
  • [Cites] Radiology. 2007 Apr;243(1):258-67 [17293571.001]
  • [Cites] Acta Radiol. 2007 Apr;48(3):327-30 [17453505.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S49-60 [17486052.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • (PMID = 18492904.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB001981-07; United States / NIBIB NIH HHS / EB / R01 EB001981-08; United States / NIBIB NIH HHS / EB / R01 EB001981; United States / NIBIB NIH HHS / EB / EB001981; United States / NIBIB NIH HHS / EB / R01 EB001981-07; United States / NIBIB NIH HHS / EB / EB001981-08
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS196000; NLM/ PMC2894569
  •  go-up   go-down


5. Riddick AC, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, Sethia KK, Ellis V, Collins AT, Maitland NJ, Ball RY, Edwards DR: Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer; 2005 Jun 20;92(12):2171-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracellular proteases of the matrix metalloproteinase (MMP) and serine protease families participate in many aspects of tumour growth and metastasis.
  • Using quantitative real-time RT-PCR analysis, we have undertaken a comprehensive survey of the expression of these enzymes and of their natural inhibitors in 44 cases of human prostate cancer and 23 benign prostate specimens.
  • We found increased expression of MMP10, 15, 24, 25 and 26, urokinase plasminogen activator-receptor (uPAR) and plasminogen activator inhibitor-1 (PAI1), and the newly characterised serine proteases hepsin and matriptase-1 (MTSP1) in malignant tissue compared to benign prostate tissue.
  • The cellular localisation of the expression of the deregulated genes was evaluated using primary malignant epithelial and stromal cell cultures derived from radical prostatectomy specimens.
  • [MeSH-major] Matrix Metalloproteinases / genetics. Prostatic Neoplasms / genetics. Serine Endopeptidases / genetics. Tissue Inhibitor of Metalloproteinases / genetics
  • [MeSH-minor] Aged. Disease Progression. GPI-Linked Proteins. Gene Expression Profiling. Humans. Male. Membrane Glycoproteins / biosynthesis. Membrane Glycoproteins / genetics. Middle Aged. Prognosis. Prostate / metabolism. Prostate / pathology. Prostatectomy. RNA, Messenger. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2002 Oct;42(4):398-406 [12361907.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):46845-8 [12384513.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6812-6 [12460890.001]
  • [Cites] Cancer Detect Prev. 2002;26(6):435-43 [12507228.001]
  • [Cites] J Urol. 2003 Mar;169(3):1157-61 [12576872.001]
  • [Cites] BJU Int. 2003 Mar;91(4):315-23; discussion 323-4 [12603403.001]
  • [Cites] J Urol. 2003 Apr;169(4):1316-9 [12629351.001]
  • [Cites] Mol Cancer Res. 2003 Mar;1(5):333-45 [12651907.001]
  • [Cites] Nat Med. 2003 Apr;9(4):407-15 [12652295.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):198-206 [15386409.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Dec;229(11):1090-6 [15564434.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55540-4 [15501821.001]
  • [Cites] Urol Res. 2005 Feb;33(1):44-50 [15517230.001]
  • [Cites] Prostate. 2000 Jan;42(1):18-25 [10579795.001]
  • [Cites] Ann Oncol. 2000 Mar;11(3):327-32 [10811500.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):879-82 [10854562.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 [10949579.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36720-5 [10962009.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6927-34 [11156392.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2365-70 [11289097.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1301-11 [11290548.001]
  • [Cites] Expert Rev Mol Med. 2003 Sep;5(23):1-39 [14585170.001]
  • [Cites] Nat Genet. 2003 Nov;35(3):252-7 [14517555.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 26;312(4):1196-201 [14652000.001]
  • [Cites] J Urol. 2004 Jan;171(1):187-91 [14665873.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3937-44 [14666700.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8511-5 [14679018.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):463-70 [14735194.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):845-51 [14647437.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):590-8 [14744773.001]
  • [Cites] Oncogene. 2003 Apr 10;22(14):2121-34 [12687014.001]
  • [Cites] Curr Top Dev Biol. 2003;54:263-312 [12696753.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):15056-64 [12586837.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2292-9 [12727852.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):453-9 [12798711.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7847-52 [12788977.001]
  • [Cites] Int J Cancer. 2003 Sep 1;106(3):382-7 [12845678.001]
  • [Cites] J Histochem Cytochem. 2003 Aug;51(8):1017-25 [12871983.001]
  • [Cites] Eur J Haematol. 2003 Aug;71(2):91-9 [12890147.001]
  • [Cites] Adv Exp Med Biol. 2003;532:91-107 [12908552.001]
  • [Cites] Exp Cell Res. 2003 Aug 15;288(2):246-56 [12915116.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(3):217-22 [12970724.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):40364-72 [12904305.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6758-62 [14583471.001]
  • [Cites] J Biol Chem. 1997 Apr 4;272(14):9147-52 [9083044.001]
  • [Cites] Clin Exp Metastasis. 1997 May;15(3):246-58 [9174126.001]
  • [Cites] Oncogene. 1997 Jun 12;14(23):2767-74 [9190892.001]
  • [Cites] J Urol. 1998 Nov;160(5):1872-6 [9783977.001]
  • [Cites] J Clin Invest. 1998 Dec 1;102(11):2002-10 [9835626.001]
  • [Cites] Prostate. 1999 May;39(2):123-9 [10221568.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2570-6 [10363975.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2094-102 [10473092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11054-61 [10500122.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):952-61 [14871825.001]
  • [Cites] Prostate. 2004 May 1;59(2):167-76 [15042617.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):155-69 [15069676.001]
  • [Cites] Chest. 2004 May;125(5):1843-52 [15136399.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):185-95 [15324701.001]
  • [Cites] J Immunol. 2004 Sep 15;173(6):3605-11 [15356104.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):228-35 [15368474.001]
  • [Cites] J Urol. 1974 Jan;111(1):58-64 [4813554.001]
  • [Cites] J Mol Biol. 1990 Oct 5;215(3):403-10 [2231712.001]
  • [Cites] J Cancer Res Clin Oncol. 1991;117(2):144-50 [1848860.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4493-8 [7691397.001]
  • [Cites] Am J Pathol. 1994 Mar;144(3):585-91 [8129044.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):497-502 [11304683.001]
  • [Cites] Leuk Lymphoma. 2000 Nov;39(5-6):485-93 [11342332.001]
  • [Cites] Biochem J. 2001 Jun 15;356(Pt 3):705-18 [11389678.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):55-63 [11437402.001]
  • [Cites] Oncogene. 2001 Jul 19;20(32):4337-43 [11466614.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Annu Rev Cell Dev Biol. 2001;17:463-516 [11687497.001]
  • [Cites] J Urol. 2001 Dec;166(6):2171-7 [11696729.001]
  • [Cites] J Cell Sci. 2001 Nov;114(Pt 21):3865-72 [11719553.001]
  • [Cites] Cell. 2001 Dec 14;107(6):789-800 [11747814.001]
  • [Cites] Blood. 2002 Jan 1;99(1):258-67 [11756180.001]
  • [Cites] Anal Biochem. 2002 Jan 15;300(2):269-73 [11779121.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1101-7 [11948120.001]
  • [Cites] Oncogene. 2002 Mar 28;21(14):2245-52 [11948407.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2169-80 [12057920.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jul;3(7):509-19 [12094217.001]
  • [Cites] J Cell Sci. 2002 Oct 1;115(Pt 19):3719-27 [12235282.001]
  • [Cites] Cancer Detect Prev. 2002;26(3):222-8 [12269770.001]
  • (PMID = 15928670.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / RECK protein, human; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC2361819
  •  go-up   go-down


6. Tao Y, Lo SC, Freedman MT, Makariou E, Xuan J: Multilevel learning-based segmentation of ill-defined and spiculated masses in mammograms. Med Phys; 2010 Nov;37(11):5993-6002
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The method was tested on 54 masses (51 malignant and 3 benign), all with ill-defined margins and irregular shape or spiculations.
  • [MeSH-major] Breast Neoplasms / diagnostic imaging. Image Processing, Computer-Assisted / methods. Mammography / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2000 Jun;215(3):703-7 [10831688.001]
  • [Cites] Med Phys. 2009 Jun;36(6):2052-68 [19610294.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Apr;20(4):289-301 [11370896.001]
  • [Cites] Med Phys. 2001 Jul;28(7):1455-65 [11488579.001]
  • [Cites] IEEE Trans Med Imaging. 2004 Sep;23(9):1077-86 [15377116.001]
  • [Cites] Biometrics. 1976 Sep;32(3):619-27 [963175.001]
  • [Cites] Med Phys. 1996 Aug;23(8):1337-45 [8873030.001]
  • [Cites] IEEE Trans Med Imaging. 1997 Oct;16(5):642-52 [9368120.001]
  • [Cites] IEEE Trans Med Imaging. 1998 Aug;17(4):510-7 [9845307.001]
  • [Cites] Med Phys. 2004 Oct;31(10):2796-810 [15543787.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2004 Aug;26(8):1007-19 [15641731.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2004 Sep;26(9):1124-37 [15742889.001]
  • [Cites] IEEE Trans Med Imaging. 2006 Dec;25(12):1588-603 [17167994.001]
  • [Cites] Med Phys. 2007 Nov;34(11):4256-69 [18072490.001]
  • [Cites] Med Phys. 2008 Jan;35(1):280-90 [18293583.001]
  • [Cites] Med Phys. 2001 Feb;28(2):259-66 [11243351.001]
  • (PMID = 21158311.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R33CA102906
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2988833
  •  go-up   go-down


7. Mu T, Nandi AK, Rangayyan RM: Classification of breast masses using selected shape, edge-sharpness, and texture features with linear and kernel-based classifiers. J Digit Imaging; 2008 Jun;21(2):153-69
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast masses due to benign disease and malignant tumors related to breast cancer differ in terms of shape, edge-sharpness, and texture characteristics.
  • In this study, we evaluate a set of 22 features including 5 shape factors, 3 edge-sharpness measures, and 14 texture features computed from 111 regions in mammograms, with 46 regions related to malignant tumors and 65 to benign masses.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Biol Eng Comput. 2006 Aug;44(8):683-94 [16937210.001]
  • [Cites] Med Biol Eng Comput. 2006 Mar;44(1-2):15-26 [16929917.001]
  • [Cites] Comput Med Imaging Graph. 2007 Jun-Jul;31(4-5):198-211 [17349778.001]
  • [Cites] Med Biol Eng Comput. 2007 Aug;45(8):769-80 [17659369.001]
  • [Cites] J Digit Imaging. 2007 Sep;20(3):223-37 [17021926.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2007;2007:4911-4 [18003107.001]
  • [Cites] Med Phys. 2007 Nov;34(11):4256-69 [18072490.001]
  • [Cites] IEEE Trans Inf Technol Biomed. 2008 Jan;12(1):55-65 [18270037.001]
  • [Cites] IEEE Trans Med Imaging. 1999 Dec;18(12):1170-7 [10695529.001]
  • [Cites] Med Biol Eng Comput. 2000 Sep;38(5):487-96 [11094803.001]
  • [Cites] IEEE Trans Med Imaging. 2000 Oct;19(10):1032-43 [11131493.001]
  • [Cites] Med Phys. 2001 Jul;28(7):1455-65 [11488579.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Dec;20(12):1215-27 [11811822.001]
  • [Cites] IEEE Trans Med Imaging. 2002 Dec;21(12):1552-63 [12588039.001]
  • [Cites] IEEE Trans Med Imaging. 1997 Dec;16(6):799-810 [9533580.001]
  • [Cites] Med Phys. 1998 Apr;25(4):516-26 [9571620.001]
  • [Cites] Stat Med. 1998 May 15;17(9):1033-53 [9612889.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1795-9 [15505630.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):1-4 [15685026.001]
  • [Cites] JAMA. 2005 Mar 9;293(10):1245-56 [15755947.001]
  • [Cites] IEEE Trans Neural Netw. 2005 Mar;16(2):460-74 [15787152.001]
  • [Cites] IEEE Trans Med Imaging. 2005 Oct;24(10):1278-85 [16229415.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2006 Jan;28(1):69-74 [16402620.001]
  • [Cites] Radiology. 2006 May;239(2):375-83 [16569779.001]
  • [Cites] Phys Med Biol. 2006 Jul 7;51(13):R5-27 [16790920.001]
  • [Cites] Med Phys. 2006 Nov;33(11):4157-68 [17153394.001]
  • (PMID = 18306000.001).
  • [ISSN] 0897-1889
  • [Journal-full-title] Journal of digital imaging
  • [ISO-abbreviation] J Digit Imaging
  • [Language] ENG
  • [Grant] United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3043867
  •  go-up   go-down


8. Pakhrin B, Kang MS, Bae IH, Park MS, Jee H, You MH, Kim JH, Yoon BI, Choi YK, Kim DY: Retrospective study of canine cutaneous tumors in Korea. J Vet Sci; 2007 Sep;8(3):229-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective study of canine cutaneous tumors in Korea.
  • Out of these, 748 (25.34%) cases were diagnosed as canine cutaneous tumors in the Department of Veterinary Pathology, College of Veterinary Medicine, Seoul National University, Korea.
  • Thirty-eight different types of cutaneous tumors were identified and categorized into epithelial and melanocytic tumors (56.95%), mesenchymal tumors (38.90%), and hematopoietic tumors (4.14%) located in the skin.
  • Among these, 69.25% were benign and 30.74% were malignant.
  • The top ten most frequently diagnosed cutaneous tumors were epidermal and follicular cysts (12.70%), lipoma (11.36%), mast cell tumors (8.82%), cutaneous histiocytoma (7.49%), basal cell tumors (6.82%), sebaceous gland adenoma (6.68%), sebaceous gland hyperplasia (5.08%), hepatoid gland adenoma (3.61%), apocrine adenocarcinoma (3.07%), and fibroma (2.81%), in order of prevalence.
  • They comprised 68.45% of all cutaneous tumors.
  • These top ten cutaneous tumors were distributed on the trunk (30.08%), head and neck (20.9%), extremities (19.14%), anal and perianal area (8.59%), and tail (3.91%).
  • The age of the dogs with the ten most frequent tumors had a mean age of 8.3 years, with a range of 2 months to 19 years.
  • When all types of tumors were considered together in the entire population, there was no difference in incidence according to sex.
  • [MeSH-major] Dog Diseases / pathology. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vet Med A Physiol Pathol Clin Med. 2002 Mar;49(2):87-91 [11958472.001]
  • [Cites] Adv Vet Sci Comp Med. 1970;14:309-54 [4922146.001]
  • [Cites] Aust Vet J. 1979 Dec;55(12):602-4 [231964.001]
  • [Cites] Aust Vet J. 1983 Mar;60(3):87-8 [6603213.001]
  • [Cites] J Vet Diagn Invest. 2006 Jul;18(4):422-5 [16921890.001]
  • [Cites] Br Vet J. 1986 Jan-Feb;142(1):1-19 [3947927.001]
  • [Cites] Aust Vet J. 1987 Jun;64(6):161-4 [3115242.001]
  • [Cites] J Am Vet Med Assoc. 1992 May 15;200(10):1530-2 [1612996.001]
  • [Cites] Vet Clin North Am Small Anim Pract. 1985 May;15(3):473-92 [3874467.001]
  • (PMID = 17679768.001).
  • [ISSN] 1229-845X
  • [Journal-full-title] Journal of veterinary science
  • [ISO-abbreviation] J. Vet. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2868128
  •  go-up   go-down


9. Gromov P, Gromova I, Bunkenborg J, Cabezon T, Moreira JM, Timmermans-Wielenga V, Roepstorff P, Rank F, Celis JE: Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast. Mol Oncol; 2010 Feb;4(1):65-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulated proteins in the fluid bathing the tumour cell microenvironment as potential serological markers for early detection of cancer of the breast.
  • Here we describe a detailed analysis using gel-based proteomics in combination with mass spectrometry and immunohistochemistry (IHC) of the tumour interstitial fluids (TIF) and normal interstitial fluids (NIF) collected from 69 prospective breast cancer patients.
  • The goal of this study was to identify abundant cancer up-regulated proteins that are externalised by cells in the tumour microenvironment of most if not all these lesions.
  • To this end, we chose to use samples derived from a single tumour/benign tissue pair (patient 46, triple negative tumour), for which we had well-matched samples in terms of epithelial cell numbers, to generate the initial dataset.
  • The expression of calreticulin, cellular retinoic acid-binding protein II, chloride intracellular channel protein 1, EF-1-beta, galectin 1, peroxiredoxin-2, platelet-derived endothelial cell growth factor, protein disulfide isomerase and ubiquitin carboxyl-terminal hydrolase 5 were further validated using a tissue microarray containing 70 malignant breast carcinomas of various grades of atypia.
  • [MeSH-major] Biomarkers / metabolism. Biomarkers, Tumor / metabolism. Breast Neoplasms / diagnosis. Neoplasm Staging / classification
  • [MeSH-minor] Body Fluids / chemistry. Calreticulin / metabolism. Chloride Channels / metabolism. Early Diagnosis. Electrophoresis, Gel, Two-Dimensional / methods. Female. Galectin 1 / metabolism. Humans. Immunohistochemistry. Peptide Elongation Factor 1 / metabolism. Peroxiredoxins / metabolism. Prognosis. Protein Disulfide-Isomerases / metabolism. Proteomics / statistics & numerical data. Thymidine Phosphorylase / metabolism. Up-Regulation


10. Herrera Espiñeira C, Fernández Valdivia J, López-Cuervo JE, Martínez Tapias J: Textural analysis in the diagnosis of benign and malignant breast cells. Anal Quant Cytol Histol; 2007 Dec;29(6):365-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Textural analysis in the diagnosis of benign and malignant breast cells.
  • OBJECTIVE: To study the discriminatory capacity of textural variables to classify the nuclei of breast tumor cells as benign or malignant, using a statistical approach.
  • The sample comprised 95 cases of malignant lesions and 47 cases of benign lesions (approximately 25 nuclei per case), and 27 textural variables were measured.
  • RESULTS: The variance in gray levels was the most decisive variable in the CART analysis, correctly classifying 57% and 97% of benign and malignant cases, respectively.
  • Discriminant analysis yielded the best results, correctly classifying 79% and 85% of benign and malignant cases, respectively.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18225392.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Danova NA, Robles-Emanuelli JC, Bjorling DE: Surgical excision of primary canine rectal tumors by an anal approach in twenty-three dogs. Vet Surg; 2006 Jun;35(4):337-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision of primary canine rectal tumors by an anal approach in twenty-three dogs.
  • OBJECTIVE: To describe an anal approach for excision of primary rectal tumors in dogs and to report outcome.
  • ANIMALS: Dogs (n=23) with primary rectal tumors.
  • METHODS: Review of medical records (1990-2000) of dogs with primary rectal neoplasia excised surgically using an anal approach with rectal prolapse.
  • With dogs anesthetized, the rectum was prolapsed, stabilized with stay sutures during tumor excision with 1 cm margins to the level of the muscularis, then the rectal mucosa was sutured.
  • RESULTS: Each dog had only 1 tumor type (adenocarcinoma [8], solitary polyp [5], carcinoma [4], plasmacytoma [2], adenoma [1], leiomyoma [1], mucinous carcinoma [1], and papilloma [1]).
  • Mean tumor volume was 3.1 cm(3) (range 0.1-37.7 cm(3)).
  • The primary tumor was incompletely excised in 1 dog (4.3%), and local recurrence occurred 16 and 24 months after surgery in 2 dogs.
  • Mean postoperative disease-free interval for these 18 dogs was 36.8 months (range 5-84 months).
  • CONCLUSION: Surgical excision of tumors of the caudal rectum can be accomplished through the anus after rectal prolapse.
  • CLINICAL RELEVANCE: An anal approach facilitated by rectal prolapse should be considered as a viable option for the surgical treatment of selected cases of tumors of the caudal aspect of the rectum in dogs.
  • [MeSH-major] Anal Canal / surgery. Dog Diseases / surgery. Rectal Neoplasms / veterinary
  • [MeSH-minor] Adenocarcinoma / surgery. Adenocarcinoma / veterinary. Animals. Disease-Free Survival. Dogs. Female. Male. Polyps / surgery. Polyps / veterinary. Postoperative Complications / veterinary. Records as Topic / veterinary. Retrospective Studies. Treatment Outcome. Wisconsin / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756613.001).
  • [ISSN] 0161-3499
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Duensing A, Chin A, Wang L, Kuan SF, Duensing S: Analysis of centrosome overduplication in correlation to cell division errors in high-risk human papillomavirus (HPV)-associated anal neoplasms. Virology; 2008 Mar 1;372(1):157-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of centrosome overduplication in correlation to cell division errors in high-risk human papillomavirus (HPV)-associated anal neoplasms.
  • High-risk HPV-associated anal neoplasms are difficult to treat and biomarkers of malignant progression are needed.
  • However, a detailed analysis of centrosome overduplication in primary HPV-associated neoplasms has not been performed so far.
  • Here, we determined the frequency of centrosome overduplication in HPV-associated anal lesions using a recently identified marker for mature maternal centrioles, Cep170.
  • Remarkably, centrosome overduplication, but not aberrant centrosome numbers per se or centrosome accumulation, correlated significantly with the presence of cell division errors.
  • In addition, our experiments revealed that in particular pseudo-bipolar mitoses may play a role in the propagation of chromosomal instability in high-risk HPV-associated tumors.
  • These results provide new insights into the role of centrosome aberrations in cell division errors and encourage further studies on centrosome overduplication as a predictive biomarker of malignant progression in HPV-associated anal lesions.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol Res Commun. 1999 Sep-Dec;2(3):190-6 [10662596.001]
  • [Cites] Adv Dent Res. 2006;19(1):99-105 [16672559.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2356-60 [11289095.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):279-84 [11301343.001]
  • [Cites] Biochim Biophys Acta. 2001;1471(2):M81-8 [11342187.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] Inflamm Res. 2002 Aug;51(8):416-22 [12234059.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):815-25 [12415252.001]
  • [Cites] Virus Res. 2002 Nov;89(2):213-28 [12445661.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7075-82 [12460929.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):355-73 [15137962.001]
  • [Cites] Microbiol Mol Biol Rev. 2004 Jun;68(2):362-72 [15187189.001]
  • [Cites] Mol Cancer. 2003 Sep 8;2:30 [14498992.001]
  • [Cites] N Engl J Med. 1984 Apr 5;310(14):880-3 [6321986.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] Curr Opin Oncol. 1995 Sep;7(5):437-41 [8541389.001]
  • [Cites] Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78 [8876633.001]
  • [Cites] Acta Oncol. 1997;36(1):3-12 [9090961.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Jun;104(6):723-7 [9197877.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Aug;19(4):233-40 [9258658.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4210-3 [9331077.001]
  • [Cites] Cancer Lett. 1998 Jan 16;123(1):47-52 [9461017.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2950-5 [9501196.001]
  • [Cites] J Natl Cancer Inst Monogr. 1998;(23):15-20 [9709296.001]
  • [Cites] Mol Biol Cell. 2005 Mar;16(3):1095-107 [15616186.001]
  • [Cites] Br J Surg. 2005 Mar;92(3):277-90 [15736144.001]
  • [Cites] Cell Biol Int. 2005 May;29(5):352-9 [15890539.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):182-9 [16186736.001]
  • [Cites] Nature. 2005 Oct 13;437(7061):1043-7 [16222300.001]
  • [Cites] Curr Opin Cell Biol. 2006 Feb;18(1):74-8 [16361091.001]
  • [Cites] Cell Cycle. 2006 Dec;5(24):2899-902 [17172866.001]
  • [Cites] Int J STD AIDS. 2007 Feb;18(2):77-80 [17331275.001]
  • [Cites] Trends Cell Biol. 2007 May;17(5):215-21 [17383880.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):451-63 [17505520.001]
  • [Cites] Oncogene. 2007 Sep 20;26(43):6280-8 [17438528.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10002-7 [10944189.001]
  • (PMID = 18036631.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112598-03; United States / NCI NIH HHS / CA / R01 CA112598; United States / NCI NIH HHS / CA / R01 CA 112598; United States / NCI NIH HHS / CA / R01 CA112598-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cep170 protein, human; 0 / Phosphoproteins; 0 / Tubulin
  • [Other-IDs] NLM/ NIHMS38243; NLM/ PMC2267749
  •  go-up   go-down


13. Vorob'ev GI, Shelygin IuA, Nechushkin MI, Rybakov EG: [Results of surgical treatment of residual and recurrent anal tumors]. Khirurgiia (Mosk); 2008;(8):4-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of surgical treatment of residual and recurrent anal tumors].
  • Radio- or chemotherapy is a modern standard of anal cancer treatment.
  • The study is aimed to evaluate the role of abdominoperineal resection in the treatment of residual and recurrent anal cancer.
  • The complete tumor regression after radiotherapy/radiochemotherapy was achieved in 74(61.1%) of 120 patients with cancer-specific survival rate of 81.7%.
  • Partial tumor regression was registered in 46 of 120 patients.
  • The abdominoperineal resection was performed in 39(84.8%) of patients with the residual tumor.
  • Thus, surgical treatment allowed secondary local tumor control in 76.9% of patients with the 5-year survival rates of 69.0%.
  • The locoregional tumor relapse was diagnosed in 10(13.74%) of 74 patients with the complete tumor regression.
  • The use of abdominoperineal resection allowed the secondary local tumor control and 5 year survival.
  • Thus, abdominoperineal resection remains the method of choice in the treatment of residual and recurrent anal tumors.
  • [MeSH-major] Digestive System Surgical Procedures / methods. Neoplasm Recurrence, Local / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Endosonography. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Russia / epidemiology. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833142.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


14. Lambrinoudaki I, Augoulea A, Creatsa M, Vlachos N, Christodoulakos G, Papadias C: Endometriosis and other benign and malignant müllerian lesions in pelvic and extrapelvic organs. Anal Quant Cytol Histol; 2009 Jun;31(3):170-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometriosis and other benign and malignant müllerian lesions in pelvic and extrapelvic organs.
  • OBJECTIVE: To conduct a retrospective study on case reports found in literature across the world on benign müllerian lesions of the urogenital tract and on cases of malignant transformation from müllerian duct remnants in order to better understand these rare anatomopathologic entities and to avoid overdiagnosis and overtreatment.
  • STUDY DESIGN: We reviewed a number of case reports on benign and malignant müllerian lesions and compared the developments associated with endometriosis, endosalpingiosis and endocervicosis.
  • RESULTS: Our sampling of case reports confirm the suggestion that both malignant neoplasms and benign müllerian lesions can arise in foci of endometriosis in both pelvic and extrapelvic sites.
  • CONCLUSION: The development of malignant tumors is a well-known complication of endometriosis and endosalpingiosis, but data about endocervicosis are unclear.

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19634787.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Woenckhaus M, Grepmeier U, Werner B, Schulz C, Rockmann F, Wild PJ, Röckelein G, Blaszyk H, Schuierer M, Hofstaedter F, Hartmann A, Dietmaier W: Microsatellite analysis of pleural supernatants could increase sensitivity of pleural fluid cytology. J Mol Diagn; 2005 Oct;7(4):517-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A common diagnostic problem lies in distinguishing malignant from benign pleural effusions using routine cytological evaluation.
  • We studied pleural fluid samples obtained from 14 patients with histologically confirmed malignancy and from 6 patients with benign pleural effusions using 12 microsatellite markers from 8 different chromosomal regions.
  • Microsatellite analyses of pleural fluid supernatants showed genetic alterations in tumor patients only.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Genetic Markers / genetics. Humans. Loss of Heterozygosity / genetics. Male. Middle Aged. Neoplasms / diagnosis. Neoplasms / genetics. Neoplasms / pathology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Health Screening.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Jan 21;18(3):643-50 [9989814.001]
  • [Cites] Eur Respir J. 1997 Feb;10(2):476-81 [9042652.001]
  • [Cites] Pathol Res Pract. 1996 Dec;192(12):1206-10 [9182290.001]
  • [Cites] J Oral Pathol Med. 1997 Aug;26(7):322-6 [9250932.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1366-73 [9308707.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4749-56 [9354436.001]
  • [Cites] Ann Thorac Surg. 1997 Oct;64(4):941-4 [9354505.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2028-32 [10580028.001]
  • [Cites] Anal Cell Pathol. 1999;19(1):7-20 [10661621.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):341-7 [10023701.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 17;91(4):332-9 [10050866.001]
  • [Cites] Diagn Cytopathol. 1999 Jun;20(6):350-7 [10352907.001]
  • [Cites] Surg Oncol Clin N Am. 1999 Oct;8(4):641-56, vi [10452932.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2297-303 [10499596.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(1):65-73 [10505546.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7335-46 [15534110.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2502-9 [15814626.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Internist (Berl). 1996 Sep;37(9):959-68; quiz 968 [8964697.001]
  • [Cites] Anal Cell Pathol. 1996 Nov;12(2):85-98 [8986293.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1508-14 [10667431.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):707-11 [10676657.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2488-91 [10811129.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):448-55 [10821492.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3155-9 [10866304.001]
  • [Cites] Cancer. 2000 Aug 25;90(4):258-63 [10966568.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5954-8 [11085511.001]
  • [Cites] Int J Cancer. 2001 Jan 15;91(2):200-4 [11146445.001]
  • [Cites] Cancer. 2001 Feb 25;93(1):68-72 [11241268.001]
  • [Cites] Cancer Lett. 2001 Apr 10;165(1):63-9 [11248420.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4675-8 [11406535.001]
  • [Cites] Chest. 2001 Jul;120(1):50-4 [11451815.001]
  • [Cites] Diagn Cytopathol. 2001 Oct;25(4):225-30 [11599105.001]
  • [Cites] Cancer. 2001 Oct 25;93(5):293-308 [11668464.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Oct 1;164(7):1312-8 [11673227.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):35-40 [11801538.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2370-7 [11956099.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):210-9 [11990857.001]
  • [Cites] Eur Urol. 2002 Jun;41(6):668-76 [12074786.001]
  • [Cites] Anal Cell Pathol. 2002;24(1):5-15 [12122279.001]
  • [Cites] Int J Cancer. 2002 Aug 10;100(5):534-41 [12124802.001]
  • [Cites] Lab Invest. 2002 Sep;82(9):1147-53 [12218075.001]
  • [Cites] Diagn Cytopathol. 2002 Oct;27(4):210-3 [12357497.001]
  • [Cites] Ann Pathol. 2002 Sep;22(4):277-88 [12410150.001]
  • [Cites] J Gastroenterol. 2002;37(10):831-9 [12424567.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):172-7 [12800191.001]
  • [Cites] Pathol Res Pract. 2003;199(6):355-62 [12924435.001]
  • [Cites] Eur J Haematol. 2003 Sep;71(3):174-8 [12930317.001]
  • [Cites] Histol Histopathol. 2003 Oct;18(4):1053-7 [12973674.001]
  • [Cites] Biogerontology. 2003;4(4):233-50 [14501188.001]
  • [Cites] Int J Oncol. 2003 Nov;23(5):1357-63 [14532977.001]
  • [Cites] Clin Lab Med. 2003 Sep;23(3):729-54, viii [14560537.001]
  • [Cites] Pancreas. 2004 Jan;28(1):13-9 [14707724.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jan;83(2):119-28 [14997042.001]
  • [Cites] Lung Cancer. 2004 Apr;44(1):33-42 [15013581.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2716-26 [15048096.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):96-100 [15185349.001]
  • [Cites] Clin Med. 2004 May-Jun;4(3):207-10 [15244350.001]
  • [Cites] Breast Cancer Res Treat. 2004 Sep;87(1):23-31 [15377848.001]
  • [Cites] Int J Cancer. 2004 Nov 20;112(4):643-6 [15382045.001]
  • [Cites] Diagn Cytopathol. 2004 Oct;31(4):246-54 [15452897.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Jan 15;19(3-4):271-9 [3943048.001]
  • [Cites] Eur J Respir Dis. 1985 Nov;67(5):326-34 [4085584.001]
  • [Cites] Cancer Res. 1990 Nov 15;50(22):7166-73 [1977514.001]
  • [Cites] Mod Pathol. 1991 May;4(3):320-4 [2068057.001]
  • [Cites] Int J Cancer. 1992 Oct 21;52(4):534-7 [1399132.001]
  • [Cites] Mol Cell Endocrinol. 1993 Apr;92(2):153-60 [8319825.001]
  • [Cites] Nat Med. 1996 Sep;2(9):1035-7 [8782464.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Nov;20(3):268-74 [9365834.001]
  • [Cites] Electrophoresis. 1997 Sep;18(10):1742-9 [9372265.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):113-6 [9541693.001]
  • [Cites] Gynecol Oncol. 1999 Jan;72(1):3-9 [9889022.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):83-95 [9916922.001]
  • (PMID = 16237222.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC1888495
  •  go-up   go-down


16. Kidd EA, Dehdashti F, Siegel BA, Grigsby PW: Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol; 2010 Jun;95(3):288-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis.
  • PURPOSE: To evaluate anal cancer uptake of F-18 fluorodeoxyglucose (FDG) measured as the maximum standardized uptake value (SUV(max)) by positron emission tomography (PET) and its correlation with prognostic factors.
  • PATIENTS AND METHODS: The study population consisted of 77 patients with stages 0-IIIB anal cancer who underwent pre-treatment FDG-PET.
  • Tumor histology included 65 squamous cell, 11 basaloid, and 1 small cell cancers.
  • SUV(max) and clinical tumor size were not associated (R(2)=0.338).
  • Higher SUV(max) was associated with an increased risk of nodal metastasis at diagnosis (p<0.0001).
  • Higher SUV(max) was associated with worse disease-free survival (p=0.05).
  • Patients with high anal tumor SUV(max) at diagnosis were at an increased risk of persistent or recurrent disease on post-therapy FDG-PET performed less than 4months after completing therapy (p=0.0402).
  • CONCLUSIONS: SUV(max) is a valuable biomarker of anal cancer prognosis, predicting increased risk of lymph node metastasis and worse disease-free survival.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18 / pharmacokinetics. Positron-Emission Tomography. Radiopharmaceuticals / pharmacokinetics

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20231040.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


17. Messadi M, Bessaid A, Taleb-Ahmed A: Extraction of specific parameters for skin tumour classification. J Med Eng Technol; 2009;33(4):288-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraction of specific parameters for skin tumour classification.
  • In this paper, a methodological approach to the classification of tumour skin lesions in dermoscopy images is presented.
  • Melanomas are the most malignant skin tumours.
  • This type of cancer is increasing rapidly; its related mortality rate is increasing more modestly, and inversely proportional to the thickness of the tumour.
  • Using skin tumour features such as colour, symmetry and border regularity, an attempt is made to determine if the skin tumour is a melanoma or a benign tumour.
  • In this work, we are interested in extracting specific attributes which can be used for computer-aided diagnosis of melanoma, especially among general practitioners.
  • In the second step, an automatic segmentation is applied to the image of the skin tumour.
  • This step is essential to characterize the shape of the lesion and also to locate the tumour for analysis.
  • Then, a sequences of transformations is applied to the image to measure a set of attributes (A: asymmetry, B: border, C: colour and D: diameter) which contain sufficient information to differentiate a melanoma from benign lesions.
  • Finally, the various signs of specific lesion (ABCD) are provided to an artificial neural network to differentiate between malignant tumours and benign lesions.
  • [MeSH-major] Image Interpretation, Computer-Assisted / methods. Melanoma / diagnosis. Pattern Recognition, Automated / methods. Skin Neoplasms

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dermatol. 1999 Dec;135(12):1459-65 [10606050.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Mar;20(3):233-9 [11341712.001]
  • [Cites] Comput Med Imaging Graph. 1992 May-Jun;16(3):191-7 [1623494.001]
  • [Cites] Anal Quant Cytol Histol. 1993 Feb;15(1):1-11 [8471104.001]
  • [Cites] Comput Biol Med. 1997 Nov;27(6):533-43 [9437554.001]
  • [Cites] Med Biol Eng Comput. 2005 Jul;43(4):436-42 [16255424.001]
  • [Cites] Comput Med Imaging Graph. 2007 Sep;31(6):362-73 [17387001.001]
  • (PMID = 19384704.001).
  • [ISSN] 1464-522X
  • [Journal-full-title] Journal of medical engineering & technology
  • [ISO-abbreviation] J Med Eng Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2683694
  •  go-up   go-down


18. Tytherleigh MG, Birtle AJ, Cohen CE, Glynne-Jones R, Livingstone J, Gilbert J: Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour. Surgeon; 2006 Dec;4(6):378-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour.
  • BACKGROUND: The Buschke-Löwenstein tumour (BLT) or giant condyloma acuminata is a rare disease which affects the anogenital region.
  • Although histologically benign, it behaves in a malignant fashion, infiltrating the surrounding tissues.
  • The morbidity and mortality from this tumour is high, as is the risk of recurrence following treatment.
  • It lies on the continuum between the benign condylomata acuminata and squamous cell carcinoma.
  • Chemoradiation remains the mainstay of treatment for anal cancers but has not been routinely employed in the management of the BLT without squamous cell carcinoma transformation.
  • RESULTS: The first patient had a good symptomatic response to the chemoradiation but unfortunately died of recurrent disease following surgery.
  • CONCLUSION: Pre-operative chemoradiation has proved to be useful in management for histologically proven benign BLT
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Condylomata Acuminata / therapy. Neoadjuvant Therapy. Perineum / pathology. Perineum / surgery. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Abdominal Neoplasms / secondary. Abdominal Neoplasms / therapy. Adult. Anus Neoplasms / secondary. Anus Neoplasms / therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / therapy. Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Fatal Outcome. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Rectal Neoplasms / secondary. Rectal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Genital Warts.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17152203.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Collinson RJ, McC Mortensen NJ: 'How I do it': TEM for tumors of the rectum. J Gastrointest Surg; 2009 Feb;13(2):359-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'How I do it': TEM for tumors of the rectum.
  • INTRODUCTION: Transanal endoscopic microsurgery (TEM) has an established role in the management of benign rectal tumors.
  • It also has an expanding role in the management of malignant tumors, which is more demanding for the clinician.
  • This paper discusses our institutional approach to TEM for benign and malignant tumors and covers some of the current management controversies.
  • [MeSH-major] Microsurgery / methods. Proctoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Anal Canal / surgery. Humans. Postoperative Care. Preoperative Care. Proctoscopes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):429-37 [15747069.001]
  • [Cites] Dis Colon Rectum. 2002 May;45(5):601-4 [12004207.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1286-95 [7497841.001]
  • [Cites] Endoscopy. 1985 Jan;17(1):31-5 [3971938.001]
  • [Cites] Dig Surg. 2006;23(1-2):12-22 [16675907.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] Int J Colorectal Dis. 2001 Nov;16(6):370-6 [11760898.001]
  • [Cites] Surg Endosc. 2006 Aug;20(8):1203-7 [16703429.001]
  • [Cites] Rev Esp Enferm Dig. 2006 Apr;98(4):234-40 [16792452.001]
  • [Cites] Br J Surg. 2007 May;94(5):627-33 [17335125.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):177-81 [7851173.001]
  • [Cites] Int J Colorectal Dis. 1986 Apr;1(2):79-84 [3611938.001]
  • [Cites] Colorectal Dis. 2000 Sep;2(5):252-63 [23578114.001]
  • [Cites] Dis Colon Rectum. 2001 Sep;44(9):1345-61 [11584215.001]
  • (PMID = 18461419.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Pérez Pereyra J, Frisancho Velarde O, Ruiz Barahona E, Palomino A: [Fibroepithelial lesions of the anal canal: therapeutic technique with rubber band ligation]. Rev Gastroenterol Peru; 2008 Jan-Mar;28(1):37-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fibroepithelial lesions of the anal canal: therapeutic technique with rubber band ligation].
  • [Transliterated title] Lesiones Fibroepiteliales del Canal Anal: alternativa terapéutica con ligadura de bandas elásticas.
  • When fibroepithelial lesions of the anal canal increase in size and bleed, they can produce tenesmus and a sensation of a foreign body in the anus.
  • In the Gastroenterology Department of the "Edgardo Rebagliati Martins" National Hospital (EsSALUD) between June 2000, and June, 2007, 16 patients with anal fibroepithelioma were included: 6 men and 10 women, with an average age of 44, aged between 21 to 75, and 44% aged 20 to 29.
  • All of these patients (100%) had anal tumors, 50% had prolapses, 28% had anal pain and, 12% intermittent slight bleeding.
  • Patients only required oral analgesics for the first hours after procedure; only one patient presented an acute anal fissure.
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Fibroepithelial / therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418455.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


21. Nair BC, Kumar S, Rani S, Paliwal OP: Analysis of karyometric variables in spontaneously occurring canine mammary tumors. Anal Quant Cytol Histol; 2006 Oct;28(5):292-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of karyometric variables in spontaneously occurring canine mammary tumors.
  • OBJECTIVE: To study alteration in karyometric variables to distinguish benign from malignant canine mammary tumors.
  • STUDY DESIGN: Formalin-fixed, paraffin-embedded tissue sections from 16 cases of canine mammary tumors were stained with hematoxylin-eosin and analyzed for mean nuclear area, mean nuclear perimeter and shape factor.
  • The morphometric descriptors were then correlated with conventional histologic diagnosis.
  • RESULTS: On Mann-Whitney U-test, nuclear variables, that is, mean nuclear area and mean nuclear perimeter, revealed significant difference between malignant and benign groups (p < 0.01), while shape factor showed significant difference at p < 0.05.
  • All morphometric descriptors showed significant correlation with each other and with histopathologic diagnosis.
  • Contrary to expectations, shape factor was lower in benign compared to malignant tumors.
  • In benign mammary tumors, the highest mean nuclear area and perimeter were 39.59 +/- 10.34 microm2 and 25.39 +/- 4.14 microm, respectively, for fibroadenoma; and in malignant tumors the highest mean nuclear area and perimeter were 48.44 +/- 12.89 microm2 and 27.36 +/- 4.31 microm, respectively, for papillary adenocarcinoma.
  • CONCLUSION: This study provides insight into the alterations in karyometric variables in canine mammary tumors.
  • Mean nuclear area and perimeter appear to have potential to differentiate benign and malignant canine mammary tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067011.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Mudrikova T, Jaspers C, Ellerbroek P, Hoepelman A: HPV-related anogenital disease and HIV infection: not always 'ordinary' condylomata acuminata. Neth J Med; 2008 Mar;66(3):98-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HPV-related anogenital disease and HIV infection: not always 'ordinary' condylomata acuminata.
  • Human papillomavirus (HPV) is responsible for various diseases in the anogenital region which range from benign condylomata acuminata to anal carcinoma.
  • Buschke-Loewenstein tumour is a clinically 'intermediate' condition which is histologically benign but due to extensive destruction of the local tissues can show malignant behaviour.
  • Immunocompromised persons, such as those with HIV infection, have a higher incidence of HPV-related anogenital disease.
  • Different aspects of the HPV-related anogenital disease in HIV-positive individuals are discussed.
  • [MeSH-major] Alphapapillomavirus. Anus Neoplasms / virology. Genital Neoplasms, Female / virology. Genital Neoplasms, Male / virology. HIV Infections / complications. Papillomavirus Infections / complications. Precancerous Conditions / virology. Skin Neoplasms / virology. Tumor Virus Infections / complications
  • [MeSH-minor] Condylomata Acuminata / diagnosis. Condylomata Acuminata / virology. Female. Humans. Male. Prognosis. Risk Factors


23. Baatrup G, Bolstad M, Mortensen JH: Rigid sigmoidoscopy and MRI are not interchangeable in determining the position of rectal cancers. Eur J Surg Oncol; 2009 Nov;35(11):1169-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE:. 1) To analyse for interchangeability of rigid sigmoidoscopy and MRI in determining the distance from anus to tumour, and to determine if anterior/posterior location influences this difference.
  • 2) To analyse the effect of preoperative chemo-radiotherapy on the distance from anus to tumour.
  • RESULTS: The mean distance from the anal verge to the tumour measured by sigmoidoscopy was 82mm and by MRI 61mm (p<0.01).
  • The length of the tumours decreased by 16mm after neoadjuvant treatment, but the distance from tumour to anus increased by only 4mm. CONCLUSION:.
  • 1) MRI and sigmoidoscopy are not interchangeable in determining the distance from anus to tumour simply by correcting for the length of the anal canal.
  • 2) The gain in tumour free distance above the anus induced by neoadjuvant treatment is small.
  • [MeSH-major] Anal Canal / pathology. Magnetic Resonance Imaging / methods. Rectal Neoplasms / pathology. Sigmoidoscopy / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249188.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


24. Yang BL, Gu YF, Shao WJ, Chen HJ, Sun GD, Jin HY, Zhu X: Retrorectal tumors in adults: magnetic resonance imaging findings. World J Gastroenterol; 2010 Dec 14;16(46):5822-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrorectal tumors in adults: magnetic resonance imaging findings.
  • AIM: To retrospectively evaluate the magnetic resonance imaging (MRI) features of adult retrorectal tumors and compare with histopathologic findings.
  • METHODS: MRI features of 21 patients with preoperative suspicion of retrorectal tumors were analyzed based on the histopathological and clinical data.
  • RESULTS: Fourteen benign cystic lesions appeared hypointense on T1-weighted images, and hyperintense on T2-weighted images with regular peripheral rim.
  • Six solid tumors were malignant lesions and showed heterogeneous intensity on MRI.
  • There was a fistula between the mass and anus with an internal opening in mucinous adenocarcinomas arising from anal fistula.
  • Gastrointestinal stromal tumors displayed low signal intensity on T1-weighted images, and intermediate to high signal intensity on T2-weighted images.
  • CONCLUSION: MRI is a helpful technique to define the extent of the retrorectal tumor and its relationship to the surrounding structures, and also to demonstrate possible complications so as to choose the best surgical approach.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Rectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1985 Nov;28(11):855-8 [4053899.001]
  • [Cites] Eur Radiol. 2004 Oct;14(10):1926-9 [15300393.001]
  • [Cites] Oncology. 1993 Nov-Dec;50(6):495-9 [8233293.001]
  • [Cites] J Comput Assist Tomogr. 1997 Sep-Oct;21(5):731-2 [9294562.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jun;170(6):1488-90 [9609159.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):1056-8 [9715165.001]
  • [Cites] Clin Imaging. 2005 Jul-Aug;29(4):251-4 [15967315.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1581-7 [15937630.001]
  • [Cites] Yonsei Med J. 2005 Aug 31;46(4):555-61 [16127782.001]
  • [Cites] AJR Am J Roentgenol. 2006 Aug;187(2):517-21 [16861558.001]
  • [Cites] Int J Colorectal Dis. 2007 Apr;22(4):381-5 [16909248.001]
  • [Cites] Br J Surg. 2008 Feb;95(2):214-21 [17933000.001]
  • [Cites] Abdom Imaging. 2008 Jul-Aug;33(4):498-500 [17680300.001]
  • [Cites] Eur Radiol. 2008 Nov;18(11):2586-93 [18566821.001]
  • [Cites] Can J Surg. 2008 Dec;51(6):E115-6 [19057717.001]
  • [Cites] Am Surg. 2009 Mar;75(3):240-8 [19350861.001]
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1344-7 [10811351.001]
  • [Cites] Radiographics. 2001 May-Jun;21(3):575-84 [11353107.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):705-14 [12023574.001]
  • [Cites] Tech Coloproctol. 2002 Apr;6(1):43-9 [12077641.001]
  • [Cites] Hum Pathol. 2002 May;33(5):456-8 [12094369.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):655-64 [12424067.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S39-51 [12528772.001]
  • [Cites] Surg Oncol. 2003 Jul;12(1):21-6 [12689667.001]
  • [Cites] Tech Coloproctol. 2003 Apr;7(1):55-7 [12750956.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):880-6 [12788424.001]
  • [Cites] Eur Radiol. 2003 Aug;13(8):2053-4 [12942309.001]
  • [Cites] Dis Colon Rectum. 1985 Sep;28(9):644-52 [2996861.001]
  • (PMID = 21155003.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3001973
  •  go-up   go-down


25. Winder DM, Ball SL, Vaughan K, Hanna N, Woo YL, Fränzer JT, Sterling JC, Stanley MA, Sudhoff H, Goon PK: Sensitive HPV detection in oropharyngeal cancers. BMC Cancer; 2009 Dec 15;9:440
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Human papillomaviruses (HPV) are the aetiological agents of certain benign and malignant tumours of skin and mucosae; the most important of which is cervical cancer.
  • Also, the incidence of ano-genital warts, HPV-anal cancer and oropharyngeal cancers are rising.
  • METHODS: We compared PGMY09/11, MY09/11 and GP5+/6+ primers sets in PCRs of 34 clinically diagnosed samples of genital warts, cervical brushings (with associated histological diagnosis) and vulval biopsies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 2000 Jan;38(1):357-61 [10618116.001]
  • [Cites] Eur J Cancer. 2009 Nov;45(17):2935-9 [19766476.001]
  • [Cites] Diagn Mol Pathol. 2000 Sep;9(3):151-7 [10976722.001]
  • [Cites] Laryngoscope. 2001 Jan;111(1):57-69 [11192901.001]
  • [Cites] N Engl J Med. 2001 Apr 12;344(15):1125-31 [11297703.001]
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] Int J Cancer. 2002 Jan 1;97(1):72-81 [11774246.001]
  • [Cites] J Infect Dis. 2002 Jun 15;185(12):1794-7 [12085327.001]
  • [Cites] Clin Exp Dermatol. 2002 Oct;27(7):571-7 [12464152.001]
  • [Cites] Clin Microbiol Rev. 2003 Jan;16(1):1-17 [12525422.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Oral Oncol. 2003 Dec;39(8):821-8 [13679205.001]
  • [Cites] J Clin Virol. 2004 Aug;30(4):302-8 [15163418.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Jul;98(1):91-6 [15243477.001]
  • [Cites] Ann Oncol. 2004 Aug;15(8):1179-86 [15277256.001]
  • [Cites] J Virol Methods. 2004 Dec 1;122(1):87-93 [15488625.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] Nature. 1989 May 18;339(6221):237-8 [2716852.001]
  • [Cites] J Clin Microbiol. 1992 Apr;30(4):987-92 [1315341.001]
  • [Cites] Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78 [8876633.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] J Clin Microbiol. 1997 Jun;35(6):1304-10 [9163434.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):744-54 [15599852.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S82-90 [15753016.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8636-45 [16275937.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] J Virol Methods. 2007 Jun;142(1-2):226-30 [17320976.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):143-50 [17354235.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):612-9 [18235120.001]
  • [Cites] Curr HIV/AIDS Rep. 2008 May;5(2):78-85 [18510893.001]
  • [Cites] Ann Oncol. 2008 Oct;19(10):1681-90 [18558666.001]
  • [Cites] Cancer. 2008 Nov 15;113(10 Suppl):3036-46 [18980286.001]
  • [Cites] J Infect Dis. 2009 May 1;199(9):1263-9 [19320589.001]
  • [Cites] BMC Infect Dis. 2009;9:74 [19473489.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):651-5 [10655362.001]
  • (PMID = 20003490.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2803197
  •  go-up   go-down


26. Stanley JD, Bell C, Hinkle N, Moore RA, Burns RP: The Ferguson Operating Anoscope as a minimally invasive option for the treatment of rectal tumors. Am Surg; 2010 Aug;76(8):850-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Ferguson Operating Anoscope as a minimally invasive option for the treatment of rectal tumors.
  • Transanal excision of rectal tumors may be performed using the Ferguson Operating Anoscope (FOA).
  • This retrospective case series evaluates the effectiveness of FOA for the excision of selected benign and malignant rectal tumors.
  • The office records of 97 patients with rectal tumors who underwent FOA transanal excision by a single surgeon from 1999 through 2009 were reviewed.
  • In the 97 patients evaluated, 99 FOA transanal excisions were performed for 39 adenocarcinomas, 55 benign tumors, and five carcinoid tumors.
  • The tumors were 0.5 to 13.5 cm in diameter and located an average of 6.9 cm (range, 1 to 15 cm) from the anal verge.
  • Ninety-one per cent of cases were performed as an outpatient.
  • Postoperative complications occurred in 14 per cent with transient effects on continence in 2 per cent and a mean blood loss of 66 mL.
  • The recurrence rate for favorable T1 rectal cancers was 4.3 per cent and for adenomas was 5.9 per cent.
  • In early follow up of adenomas and favorable T1 carcinomas, FOA transanal excision has similar application, morbidity, and recurrence rates as reported for transanal endoscopic microsurgery for rectal tumors within 15 cm from the anal verge.
  • FOA may be considered a useful option for the minimally invasive treatment of rectal tumors.
  • [MeSH-major] Digestive System Surgical Procedures / instrumentation. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoid Tumor / surgery. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures / instrumentation. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726416.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Qian W, Zhukov T, Song D, Tockman MS: Computerized analysis of cellular features and biomarkers for cytologic diagnosis of early lung cancer. Anal Quant Cytol Histol; 2007 Apr;29(2):103-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computerized analysis of cellular features and biomarkers for cytologic diagnosis of early lung cancer.
  • OBJECTIVE: To present a set of novel computerized analysis algorithms to construct a computer-aided cytologic diagnosis (CACD) system to differentiate lung cancer biomarkers and identify cancer cells in the tissue-based specimen images.
  • STUDY DESIGN: Molecular methods, including application of cancer-specific markers, may prove to be complementary to cytology diagnosis, especially when they are combined with CACD system for biomarker assessment.
  • CONCLUSION: The presented algorithms and CACD system for cellular feature enhancement, segmentation and classification are very important in distinguishing benign and malignant lesions.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484274.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Berman DM, Wincovitch S, Garfield S, Romeo MJ: Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index. J Clin Pathol; 2005 Nov;58(11):1206-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although nucleic acid derangements are the hallmark of melanocytic dysplasia, the gold standard for its diagnosis remains the microscopic evaluation of haematoxylin and eosin stained slides.
  • RESULTS: When applied to benign naevi, dysplastic naevi, and melanoma, a very strong significant association was seen between lower NAI and malignant potential (p < 0.0001).
  • Interestingly, the NAI for dysplastic naevi is between that of melanoma and most benign naevi, consistent with their intermediate biological behaviour and histological appearance.
  • CONCLUSION: By providing a quantitative measure for melanocytic neoplasia, the NAI may improve the diagnosis of melanocytic lesions and the selection of treatment.
  • [MeSH-major] DNA, Neoplasm / analysis. Dysplastic Nevus Syndrome / diagnosis. Melanoma / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Image Processing, Computer-Assisted / methods. Melanocytes / pathology. Microscopy, Confocal / methods. Mitotic Index. Nevus, Pigmented / diagnosis. Nevus, Pigmented / genetics. Nevus, Pigmented / pathology. Paraffin Embedding. RNA, Neoplasm / analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 1998 Nov;96(5):487-94 [9829812.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):419-26 [9816186.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):19-20 [12447372.001]
  • [Cites] Am J Dermatopathol. 2003 Jun;25(3):190-7 [12775980.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3081-6 [12789284.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):764-71 [12920220.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Oct;25(5):243-53 [14603721.001]
  • [Cites] Melanoma Res. 2003 Dec;13(6):581-6 [14646621.001]
  • [Cites] Br J Dermatol. 2004 Feb;150(2):179-85 [14996086.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):342-8 [15009715.001]
  • [Cites] J Am Acad Dermatol. 2004 Jul;51(1 Suppl):S65-9 [15243517.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121 Suppl:S3-32 [15298148.001]
  • [Cites] Lancet. 1977 Apr 16;1(8016):864-5 [67377.001]
  • [Cites] Arch Dermatol. 1978 May;114(5):732-8 [646394.001]
  • [Cites] Cancer Res. 1978 Jul;38(7):1893-8 [77721.001]
  • [Cites] Microsc Acta. 1981 Jan;84(1):37-42 [6163065.001]
  • [Cites] Cytometry. 1982 Jan;2(4):212-8 [6173180.001]
  • [Cites] Cytometry. 1982 Jul;3(1):28-35 [6180873.001]
  • [Cites] Am J Clin Pathol. 1985 Jun;83(6):722-5 [2408462.001]
  • [Cites] J Am Acad Dermatol. 1989 Oct;21(4 Pt 1):773-80 [2808793.001]
  • [Cites] J Cutan Pathol. 1993 Apr;20(2):121-5 [8320355.001]
  • [Cites] Kurume Med J. 1994;41(1):1-13 [7933912.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):528-31 [8666360.001]
  • [Cites] Cytometry. 1997 Feb 1;27(2):99-105 [9012376.001]
  • [Cites] Histochem Cell Biol. 1997 Apr;107(4):267-78 [9151109.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1370-7 [10717619.001]
  • (PMID = 16254113.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC1770753
  •  go-up   go-down


29. Shrikhande SV, Saoji RR, Barreto SG, Kakade AC, Waterford SD, Ahire SB, Goliwale FM, Shukla PJ: Outcomes of resection for rectal cancer in India: the impact of the double stapling technique. World J Surg Oncol; 2007;5:35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A total of 77 out of 78 patients in the SST group had Astler Coller B and C disease while the number was 132/138 in the DST group.
  • The mean distance of the tumor from anal verge was 7.6 cm (2.5-15 cm) and 8.0 cm (4-15 cm) in the DST and SST groups, respectively.
  • The observed improvement of surgical outcomes with DST needs further studies to significantly prove these findings in a population where the tumors at presentation are predominantly Astler Coller Stage B and C.
  • [MeSH-major] Adenocarcinoma / surgery. Rectal Neoplasms / surgery. Rectum / surgery. Surgical Stapling

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1983 Feb;26(2):87-90 [6822175.001]
  • [Cites] Surgery. 1980 Nov;88(5):710-4 [7434211.001]
  • [Cites] Am J Surg. 1984 Apr;147(4):524-30 [6711755.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):603-5 [3896372.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Dis Colon Rectum. 1986 Dec;29(12):885-90 [2431844.001]
  • [Cites] Int Surg. 1988 Jan-Mar;73(1):19-22 [3360572.001]
  • [Cites] Br J Surg. 1990 May;77(5):510-2 [2354332.001]
  • [Cites] Dis Colon Rectum. 1991 Apr;34(4):317-22 [2007349.001]
  • [Cites] Br J Surg. 1991 Mar;78(3):308-11 [2021845.001]
  • [Cites] Dis Colon Rectum. 1991 Jun;34(6):495-7 [2036929.001]
  • [Cites] Am Surg. 1992 Apr;58(4):270-2 [1586088.001]
  • [Cites] Br J Surg. 1992 Aug;79(8):836-8 [1393488.001]
  • [Cites] Surg Gynecol Obstet. 1992 Oct;175(4):333-6 [1329243.001]
  • [Cites] World J Surg. 1992 Sep-Oct;16(5):866-71 [1462621.001]
  • [Cites] Br J Surg. 1993 Jul;80(7):924-7 [8369941.001]
  • [Cites] Dis Colon Rectum. 1994 Feb;37(2 Suppl):S35-41 [8313790.001]
  • [Cites] Dis Colon Rectum. 1995 May;38(5):480-6; discussion 486-7 [7736878.001]
  • [Cites] Dis Colon Rectum. 1995 Dec;38(12):1246-50 [7497834.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):25-9 [9102256.001]
  • [Cites] Br J Surg. 1997 Apr;84(4):525-8 [9112908.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):747-51 [9221846.001]
  • [Cites] Surg Today. 1997;27(8):706-9 [9306583.001]
  • [Cites] Aust N Z J Surg. 1997 Sep;67(9):599-602 [9322694.001]
  • [Cites] Surgery. 1997 Oct;122(4):779-84; discussion 784-5 [9347856.001]
  • [Cites] Br J Surg. 1998 Aug;85(8):1118-20 [9718010.001]
  • [Cites] Oncology. 1999 Apr;56(3):193-7 [10202273.001]
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):284-91 [10336809.001]
  • [Cites] Indian J Gastroenterol. 1999 Jul-Sep;18(3):118-21 [10407566.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s79-81 [15655652.001]
  • [Cites] Trop Gastroenterol. 2001 Apr-Jun;22(2):83-6 [11552491.001]
  • [Cites] Br J Surg. 2001 Dec;88(12):1607-12 [11736973.001]
  • [Cites] Surg Clin North Am. 2002 Oct;82(5):983-93 [12507204.001]
  • [Cites] Int J Colorectal Dis. 2003 Nov;18(6):463-9 [14517685.001]
  • [Cites] Surg Today. 2004;34(1):32-9 [14714226.001]
  • [Cites] Br J Surg. 1980 Mar;67(3):198-200 [7362961.001]
  • [Cites] Dis Colon Rectum. 1983 Apr;26(4):231-5 [6839891.001]
  • (PMID = 17374176.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1839092
  • [General-notes] NLM/ Original DateCompleted: 20070726
  •  go-up   go-down


30. Hardie RC, Rogers SK, Wilson T, Rogers A: Performance analysis of a new computer aided detection system for identifying lung nodules on chest radiographs. Med Image Anal; 2008 Jun;12(3):240-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The JRST dataset used here is comprised of 154 chest radiographs containing one radiologist confirmed nodule each (100 malignant cases, 54 benign cases).
  • Our results indicate that the system is able to detect 78.1% of the nodules in the JRST test set with and average of 4.0 false positives per image (excluding 14 cases containing lung nodules in retrocardiac and subdiaphragmatic regions of the lung).
  • [MeSH-major] Diagnosis, Computer-Assisted / methods. Lung Diseases / radiography. Lung Neoplasms / radiography. Radiography, Thoracic / methods


31. Carino C, Olawaiye AB, Cherfils S, Serikawa T, Lynch MP, Rueda BR, Gonzalez RR: Leptin regulation of proangiogenic molecules in benign and cancerous endometrial cells. Int J Cancer; 2008 Dec 15;123(12):2782-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin regulation of proangiogenic molecules in benign and cancerous endometrial cells.
  • Here, we report that in benign (primary and HES) and cancerous-endometrial epithelial cells (EEC) (An3Ca, SK-UT2 and Ishikawa), leptin in a dose-dependent manner regulates vascular endothelial growth factor, (VEGF); interleukin-1 beta, (IL-1beta); leukemia inhibitory factor, (LIF) and their respective receptors, VEGFR2, IL-1R tI and LIFR.
  • Remarkably, leptin induces a greater increase in VEGF/VEGFR2 and LIF levels in cancer than in benign cells.
  • However, IL-1beta was only increased by leptin in benign primary-EEC.
  • Cancer-EEC expressed higher levels of leptin receptor (full-length OB-Rb and short isoforms) in contrast to benign primary-EEC.
  • Leptin's effects on proangiogenic molecules were more evident in malignant versus benign cells and may imply that there is an underlying shift in leptin-induced cell signaling pathways in endometrial cancer cells.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Endocrinology. 2005 Feb;146(2):694-701 [15539553.001]
  • [Cites] Cell. 2005 Apr 22;121(2):179-93 [15851026.001]
  • [Cites] Reproduction. 2005 Aug;130(2):131-45 [16049151.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7800-8 [16140948.001]
  • [Cites] Endocrinology. 2004 Aug;145(8):3850-7 [15142989.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Gynecol Oncol. 1991 Aug;42(2):161-4 [1832651.001]
  • [Cites] Biochem J. 2006 Jan 1;393(Pt 1):7-20 [16336196.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2840-7 [16364998.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):629-40 [16728588.001]
  • [Cites] Cancer Lett. 2006 Jul 8;238(1):61-8 [16085355.001]
  • [Cites] J Biol Chem. 2006 Sep 8;281(36):26320-8 [16825198.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4156-62 [16912221.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jan;1095:90-8 [17404022.001]
  • [Cites] J Mol Neurosci. 2007;32(1):80-9 [17873291.001]
  • [Cites] Endocrinology. 2008 Feb;149(2):506-14 [17962343.001]
  • [Cites] Annu Rev Immunol. 2000;18:143-64 [10837055.001]
  • [Cites] J Clin Endocrinol Metab. 2000 May;85(5):1946-50 [10843179.001]
  • [Cites] Mol Hum Reprod. 2000 Jul;6(7):595-601 [10871646.001]
  • [Cites] Hum Reprod Update. 2000 May-Jun;6(3):290-300 [10874574.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jul;85(7):2483-7 [10902797.001]
  • [Cites] J Cell Sci. 2000 Dec;113 Pt 23:4331-9 [11069777.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4883-8 [11134157.001]
  • [Cites] J Neurosci. 2001 Apr 1;21(7):2413-24 [11264315.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jan-Feb;11(1):54-60 [11285034.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):4747-55 [11085989.001]
  • [Cites] Exp Mol Med. 2001 Jun 30;33(2):95-102 [11460888.001]
  • [Cites] Nature. 2002 Jan 17;415(6869):339-43 [11797013.001]
  • [Cites] Endocrine. 2001 Oct;16(1):21-8 [11822823.001]
  • [Cites] Mol Hum Reprod. 2002 May;8(5):456-64 [11994543.001]
  • [Cites] Cell Signal. 2002 Aug;14(8):655-63 [12020765.001]
  • [Cites] Ann Nutr Metab. 2002;46(3-4):147-51 [12169858.001]
  • [Cites] FASEB J. 2002 Sep;16(11):1471-3 [12205052.001]
  • [Cites] Biochim Biophys Acta. 2002 Oct 21;1592(2):107-16 [12379472.001]
  • [Cites] Arthritis Rheum. 2002 Oct;46(10):2604-12 [12384918.001]
  • [Cites] J Biol Chem. 2002 Nov 1;277(44):41547-55 [12196522.001]
  • [Cites] Mol Hum Reprod. 2003 Mar;9(3):151-8 [12606591.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jun 20;306(1):139-43 [12788079.001]
  • [Cites] Int J Mol Med. 2003 Jul;12(1):95-8 [12792816.001]
  • [Cites] Mol Hum Reprod. 2003 Jul;9(7):395-8 [12802046.001]
  • [Cites] Endocrine. 2003 Jul;21(2):185-95 [12897384.001]
  • [Cites] Fertil Steril. 2003 Sep;80 Suppl 2:783-7 [14505754.001]
  • [Cites] J Biol Chem. 2003 Oct 24;278(43):42660-7 [12902351.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2737-46 [14576155.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):769-75 [14984939.001]
  • [Cites] J Surg Res. 2004 Feb;116(2):337-49 [15013374.001]
  • [Cites] Nat Rev Immunol. 2004 May;4(5):371-9 [15122202.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):698-702 [1370585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6155-9 [8327496.001]
  • [Cites] Nature. 1995 Oct 19;377(6550):591-4 [7566171.001]
  • [Cites] Nat Med. 1995 Nov;1(11):1155-61 [7584987.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6231-5 [8692797.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8374-8 [8710878.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Feb 3;231(1):26-9 [9070213.001]
  • [Cites] J Biol Chem. 1997 Mar 7;272(10):6093-6 [9102398.001]
  • [Cites] J Biol Chem. 1997 Jun 27;272(26):16216-23 [9195922.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19982-6 [9242667.001]
  • [Cites] Science. 1997 Sep 12;277(5332):1630-5 [9287210.001]
  • [Cites] Diabetologia. 1997 Nov;40(11):1358-62 [9389430.001]
  • [Cites] J Biol Chem. 1998 Aug 21;273(34):22128-35 [9705358.001]
  • [Cites] J Biol Chem. 1997 May 16;272(20):12897-900 [9148892.001]
  • [Cites] Circ Res. 1998 Nov 16;83(10):1059-66 [9815153.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1999 Aug;19(8):1835-42 [10446061.001]
  • [Cites] Hum Reprod. 1999 Oct;14(10):2485-92 [10527974.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1789-99 [15541453.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2005 Jan 10;118(1):101-8 [15596282.001]
  • [Cites] FEBS J. 2005 Jan;272(1):109-19 [15634336.001]
  • (PMID = 18798554.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098333-05; United States / NCI NIH HHS / CA / R01 CA098333; United States / PHS HHS / / R01 098333; United States / NCI NIH HHS / CA / R01 CA098333-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-1beta; 0 / LIF protein, human; 0 / Leptin; 0 / Leukemia Inhibitory Factor; 0 / Receptors, Interleukin-1; 0 / Receptors, OSM-LIF; 0 / Vascular Endothelial Growth Factor A; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ NIHMS70964; NLM/ PMC2892183
  •  go-up   go-down


32. Iqbal J, Liu T, Mapow B, Swami VK, Hou JS: Importance of flow cytometric analysis of serous effusions in the diagnosis of hematopoietic neoplasms in patients with prior hematopoietic malignancies. Anal Quant Cytol Histol; 2010 Jun;32(3):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of flow cytometric analysis of serous effusions in the diagnosis of hematopoietic neoplasms in patients with prior hematopoietic malignancies.
  • OBJECTIVE: To determine the criteria for the use of immunophenotyping by flow cytometry (FCM) in the diagnosis of hematopoietic lesions.
  • The cytopathologic diagnosis was compared with the final diagnosis as modified by subsequent FCM.
  • RESULTS: The cytopathologic diagnosis was benign in 61 cases (69%), atypical in 20 cases (22%) and malignant in 8 cases (9%).
  • In these patients, the working cytopathologic diagnosis was modified from benign/atypical to malignant in 2 (11%) cases and atypical to benign in 11 (33%) cases.
  • CONCLUSION: FCM studies were helpful in the cytopathologic diagnosis in 35% of body fluid specimens, permitting appropriate cancer staging and management.
  • In the absence of a prior clinical history, immunophenotyping by FCM in body fluid specimens should be ordered after adequacy studies when there is cytologic atypia or a strong suspicion of malignancy on the cytopathologic diagnosis.

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701070.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


33. Bullard RS, Gibson W, Bose SK, Belgrave JK, Eaddy AC, Wright CJ, Hazen-Martin DJ, Lage JM, Keane TE, Ganz TA, Donald CD: Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. Mol Immunol; 2008 Feb;45(3):839-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although it is known that innate immunity is key for protecting the body against foreign agents such as bacteria, little is known about elements of the innate immune system that have anti-tumor activity.
  • Human Beta Defensin-1 (hBD-1), an important component of the innate immune response, is lost at high frequencies in malignant prostatic tissue, while high levels of expression are maintained in adjacent benign regions.
  • In prostate carcinoma, frequent genetic alterations occur in the 8p22-23 region and several studies indicate there may be multiple tumor suppressor genes present within this region.
  • The high incidence of loss of hBD-1 expression in prostate cancer, along with its chromosomal location of 8p23.2, raised the possibility that it may play a role in tumor suppression.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Oct 15;286(5439):420-1 [10577203.001]
  • [Cites] Cancer Lett. 2007 Apr 18;248(2):251-61 [16996682.001]
  • [Cites] Oncogene. 2000 Jun 8;19(25):2921-9 [10871843.001]
  • [Cites] Int J Dev Biol. 2002;46(4):535-44 [12141441.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(17):6158-69 [12167710.001]
  • [Cites] Science. 2002 Nov 1;298(5595):977-9 [12411693.001]
  • [Cites] Genet Test. 2002 Winter;6(4):261-9 [12537649.001]
  • [Cites] Lab Invest. 2003 Apr;83(4):501-5 [12695553.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8145-55 [14603255.001]
  • [Cites] Annu Rev Immunol. 2004;22:181-215 [15032578.001]
  • [Cites] Anal Quant Cytol Histol. 2004 Jun;26(3):127-33 [15218688.001]
  • [Cites] AIDS. 2004 Jul 23;18(11):1598-600 [15238780.001]
  • [Cites] C R Biol. 2004 Jun;327(6):539-49 [15330253.001]
  • [Cites] EMBO J. 1995 Nov 15;14(22):5638-45 [8521821.001]
  • [Cites] Ann N Y Acad Sci. 1996 Oct 25;797:228-39 [8993365.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Nov;23(3):255-62 [9790507.001]
  • [Cites] Gene. 1999 Jun 11;233(1-2):205-11 [10375637.001]
  • [Cites] J Urol. 2004 Nov;172(5 Pt 2):S6-11; discussion S11-2 [15535435.001]
  • [Cites] Immunol Lett. 2005 Jan 15;96(1):3-9 [15585302.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2947-55 [15805298.001]
  • [Cites] Cell Mol Life Sci. 2005 Apr;62(7-8):784-90 [15868403.001]
  • [Cites] Carcinogenesis. 2005 Jul;26(7):1170-81 [15498784.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Mol Immunol. 2006 Apr;43(10):1617-23 [16263169.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Dec 20;266(2):532-41 [10600536.001]
  • (PMID = 17868871.001).
  • [ISSN] 0161-5890
  • [Journal-full-title] Molecular immunology
  • [ISO-abbreviation] Mol. Immunol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / C06 RR014516; United States / NCI NIH HHS / CA / K22 CA096788-03; United States / NCI NIH HHS / CA / CA096788; United States / NCI NIH HHS / CA / K22 CA096788-01A2; United States / NCRR NIH HHS / RR / C06RR14516; United States / NCI NIH HHS / CA / CA096788-02; United States / NCI NIH HHS / CA / K22 CA096788; United States / NCI NIH HHS / CA / CA096788-01A2; United States / NCI NIH HHS / CA / CA096788-03; United States / NCI NIH HHS / CA / K22 CA096788-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DEFB1 protein, human; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Proteins; 0 / beta-Defensins
  • [Other-IDs] NLM/ NIHMS34195; NLM/ PMC2131727
  •  go-up   go-down


34. Nadal SR, Calore EE, Manzione CR, Horta SC, Ferreira AF, Almeida LV: Hypertrophic herpes simplex simulating anal neoplasia in AIDS patients: report of five cases. Dis Colon Rectum; 2005 Dec;48(12):2289-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypertrophic herpes simplex simulating anal neoplasia in AIDS patients: report of five cases.
  • The analysis of our patients suggests that herpes simplex virus, Types 1 and 2, may cause verrucous lesions simulating neoplasia in patients with AIDS using antiretroviral therapy.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Anus Neoplasms / diagnosis. Herpes Simplex / diagnosis
  • [MeSH-minor] Acyclovir / therapeutic use. Adult. Anal Canal / pathology. Diagnosis, Differential. Female. Humans. Hypertrophy. Immunohistochemistry. Inflammation. Male. Middle Aged. Recurrence


35. Mora López L, Serra Aracil J, Rebasa Cladera P, Puig Divi V, Hermoso Bosch J, Bombardo Junca J, Alcántara Moral M, Hernando Tavira R, Ayguavives Garnica I, Navarro Soto S: [Anorectal disorders in the immediate and late postoperative period after transanal endoscopic microsurgery]. Cir Esp; 2007 Nov;82(5):285-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Valoración de las alteraciones de la función anorrectal en el postoperatorio inmediato y tardío tras la microcirugía transanal endoscópica.
  • INTRODUCTION AND OBJECTIVE: Transanal endoscopic microsurgery (TEM) is a new technique for local excision of benign and incipient malignant rectal lesions.
  • TEM involves prolonged dilatation of the anal sphincter with a large-diameter (4 cm) operating rectoscope.
  • Variations in anal resting pressure, maximal anal resting pressure and the anal continence questionnaire were evaluated.
  • Mean anal resting pressure (ARP) and maximal anal resting pressure (MARP) were significantly reduced at 3 weeks after surgery (ARP/MARP before surgery: 38.89/126.28; 3 weeks after surgery: 26.61/104.75).
  • [MeSH-major] Anal Canal / physiology. Fecal Incontinence / diagnosis. Microsurgery. Proctoscopy. Rectal Neoplasms / surgery

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021627.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


36. Gross G: Impact of prophylactic human papillomavirus vaccines on dermatology and venereology. G Ital Dermatol Venereol; 2008 Aug;143(4):259-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The quadrivalent HPV6, 11, 16, 18 vaccine also prevents anogenital warts (condylomata acuminata) which are the most common benign tumors of this body region.
  • Men would profit from a vaccine that protects against HPV infections, especially anogenital warts, as well as penile and anal carcinomas.
  • HPV disease can be widespread, chronic and often may rapidly progress to malignant tumors.
  • [MeSH-minor] Adolescent. Adult. Anus Neoplasms / prevention & control. Anus Neoplasms / virology. Condylomata Acuminata / prevention & control. Condylomata Acuminata / virology. Female. Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18. Humans. Male. Papilloma / prevention & control. Papilloma / virology. Penile Neoplasms / prevention & control. Penile Neoplasms / virology. Respiratory Tract Neoplasms / prevention & control. Respiratory Tract Neoplasms / virology. Sex Factors. Sexually Transmitted Diseases, Viral / prevention & control. Vulvar Neoplasms / prevention & control. Vulvar Neoplasms / virology. Young Adult

  • MedlinePlus Health Information. consumer health - HPV.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • HIV InSite. treatment guidelines - HIV InSite .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833082.001).
  • [ISSN] 0392-0488
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; 0 / Papillomavirus Vaccines
  • [Number-of-references] 53
  •  go-up   go-down


37. Monk BJ, Tewari KS: The spectrum and clinical sequelae of human papillomavirus infection. Gynecol Oncol; 2007 Nov;107(2 Suppl 1):S6-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infection with the human papillomavirus (HPV) is the most common sexually transmitted disease afflicting approximately 80% of the population.
  • In addition to cervical cancer, other malignancies in both men and women such as esophageal, oropharyngeal, and anal cancer have been causally associated with this virus.
  • HPV-16 is the most common HPV type associated with a malignant phenotype regardless of organ of origin.
  • Other non-oncogenic HPV types including HPV types 6 and 11 are associated with over 90% of benign HPV-related lesions such as genital warts and juvenile respiratory papillomatosis.
  • [MeSH-major] Papillomavirus Infections / diagnosis. Papillomavirus Infections / therapy
  • [MeSH-minor] Adult. Anus Neoplasms / virology. Child. Condylomata Acuminata / virology. Esophageal Neoplasms / virology. Female. Genital Neoplasms, Female / virology. Genital Neoplasms, Male / virology. Humans. Laryngeal Neoplasms / virology. Male. Oropharyngeal Neoplasms / virology. Papilloma / virology

  • COS Scholar Universe. author profiles.
  • eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499914.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


38. Peng Y, Jiang Y, Chuang ST, Yang XJ: Computer-aided detection of prostate cancer on tissue sections. Appl Immunohistochem Mol Morphol; 2009 Oct;17(5):442-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first set of images consisted of 20 training images (10 malignant) used for developing the computer technique and 15 test images (7 malignant) used for testing and optimizing the technique.
  • The second set of images consisted of 299 images (114 malignant) used for evaluation of the performance of the computer technique.
  • The computer technique identified image segments of alpha-methylacyl-CoA racemase-labeled malignant epithelial cells (red), p63, and high-molecular-weight cytokeratin-labeled benign basal cells (brown), and secretory and stromal cells (blue) for identifying prostate cancer automatically.
  • If high-grade prostatic intraepithelial neoplasia, which is a precursor of cancer, and atypical cases were included, the sensitivity and specificity were 85% (97/114) and 89% (165/185), respectively.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Sep;220(3):781-6 [11526282.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1151-60 [12218571.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):365-71 [12604893.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1121-31 [15343515.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):517-23 [15487448.001]
  • [Cites] Am J Surg Pathol. 1995 Mar;19(3):251-60 [7532918.001]
  • [Cites] Anal Quant Cytol Histol. 1995 Oct;17(5):314-22 [8534334.001]
  • [Cites] Pathol Res Pract. 1995 Sep;191(9):935-44 [8606876.001]
  • [Cites] Radiology. 1996 Jun;199(3):843-8 [8638015.001]
  • [Cites] Acad Radiol. 1999 Jan;6(1):22-33 [9891149.001]
  • [Cites] Abdom Imaging. 2005 Jan-Feb;30(1):26-41 [15647868.001]
  • [Cites] Am J Clin Pathol. 2005 Feb;123(2):231-6 [15842047.001]
  • [Cites] Anal Quant Cytol Histol. 2006 Feb;28(1):1-13 [16566275.001]
  • [Cites] Histopathology. 2006 May;48(6):668-73 [16681682.001]
  • [Cites] Am J Clin Pathol. 2007 Feb;127(2):248-53 [17210521.001]
  • [Cites] Nat Clin Pract Urol. 2007 Jan;4(1):39-45 [17211424.001]
  • [Cites] N Engl J Med. 2007 Apr 5;356(14):1399-409 [17409321.001]
  • [Cites] N Engl J Med. 2007 Jul 5;357(1):84; author reply 85 [17615628.001]
  • [Cites] N Engl J Med. 2007 Jul 5;357(1):84; author reply 85 [17615630.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Am J Surg Pathol. 2008 Mar;32(3):461-7 [18300803.001]
  • [Cites] AJR Am J Roentgenol. 2008 Apr;190(4):854-9 [18356428.001]
  • (PMID = 19417626.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R21 EB006466; United States / NCI NIH HHS / CA / R21 CA97308; United States / NCI NIH HHS / CA / R21 CA097308-01; United States / NCI NIH HHS / CA / CA097308-02; United States / NCI NIH HHS / CA / R01 CA092361; United States / NCI NIH HHS / CA / CA097308-01; United States / NIBIB NIH HHS / EB / EB006466-02; United States / NIBIB NIH HHS / EB / EB006466-01A1; United States / NIBIB NIH HHS / EB / R21 EB006466-01A1; United States / NIBIB NIH HHS / EB / R21 EB006466-02; United States / NCI NIH HHS / CA / R21 CA097308; United States / NCI NIH HHS / CA / R21 CA097308-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS100571; NLM/ PMC2836393
  •  go-up   go-down


39. Levenson VV: DNA methylation as a universal biomarker. Expert Rev Mol Diagn; 2010 May;10(4):481-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell-free circulating DNA carries not only tumor-specific changes in its sequence but also distinctive epigenetic marks, namely DNA methylation, in certain GC-rich fragments.
  • Analysis of DNA methylation using cell-free circulating DNA can facilitate development of very accurate biomarkers for detection, diagnosis, prediction of response to therapy and prognosis of outcomes.
  • Recent data suggest that benign and inflammatory diseases have very specific methylation patterns within cell-free circulating DNA, which are different from the pattern of a malignant tumor of the same organ.
  • In addition, specific methylation patterns have been detected for cancers of different organs, so a differential diagnosis of site-specific cancer appears feasible.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2009 Jul 7;101(1):124-31 [19536096.001]
  • [Cites] Trends Genet. 2009 Jul;25(7):288-97 [19540013.001]
  • [Cites] PLoS One. 2009;4(8):e6617 [19672297.001]
  • [Cites] Endocrinology. 2009 Sep;150(9):4003-11 [19574400.001]
  • [Cites] Semin Reprod Med. 2009 Sep;27(5):417-28 [19711252.001]
  • [Cites] Cancer Invest. 2009 Oct;27(8):877-84 [19548140.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:243-50 [12724229.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1881-7 [12932666.001]
  • [Cites] Rocz Akad Med Bialymst. 2003;48:34-41 [14737938.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4442-52 [15231653.001]
  • [Cites] Curr Opin Mol Ther. 2004 Jun;6(3):273-8 [15264429.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4933-8 [15297393.001]
  • [Cites] Am J Gastroenterol. 1990 Apr;85(4):350-5 [2183589.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Biotechniques. 1994 Mar;16(3):416-7 [8185912.001]
  • [Cites] Biochem Soc Trans. 2008 Aug;36(Pt 4):575-83 [18631120.001]
  • [Cites] Mol Cancer. 2008;7:81 [18947422.001]
  • [Cites] Int J Cancer. 2009 Feb 15;124(4):905-10 [19035455.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):40-6 [18851871.001]
  • [Cites] Expert Rev Neurother. 2009 Jan;9(1):87-98 [19102671.001]
  • [Cites] J Mol Diagn. 2009 Jan;11(1):60-5 [19074590.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):315-23 [19118060.001]
  • [Cites] Int J Urol. 2009 Jan;16(1):17-22 [18721202.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):502-10 [19147755.001]
  • [Cites] Brief Funct Genomic Proteomic. 2009 May;8(3):174-83 [19535508.001]
  • [Cites] Methods Mol Biol. 2009;590:165-76 [19763503.001]
  • [Cites] J Cell Biochem. 2009 Sep 1;108(1):3-9 [19507229.001]
  • [Cites] Biol Chem. 2009 Nov;390(11):1145-53 [19747081.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2782-9 [19755648.001]
  • [Cites] Genet Test Mol Biomarkers. 2009 Oct;13(5):623-30 [19814617.001]
  • [Cites] Expert Rev Mol Diagn. 2009 Oct;9(7):651-7 [19817550.001]
  • [Cites] Lancet Neurol. 2009 Nov;8(11):1056-72 [19833297.001]
  • [Cites] Am Fam Physician. 2009 Oct 15;80(8):815-20 [19835343.001]
  • [Cites] Int Rev Neurobiol. 2009;89:67-84 [19900616.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Dec;195(2):112-9 [19963110.001]
  • [Cites] Cancer. 2010 Apr 1;116(7):1674-80 [20143430.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Jun;136(6):847-54 [19924441.001]
  • [Cites] J Appl Physiol (1985). 2010 Sep;109(3):927-33 [20110548.001]
  • [Cites] Nucleic Acids Res. 2000 Apr 15;28(8):E32 [10734209.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3348-53 [11423985.001]
  • [Cites] Nucleic Acids Res. 2001 Jul 1;29(13):E65-5 [11433041.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;945:51-8 [11708494.001]
  • [Cites] Clin Chim Acta. 2002 Jul;321(1-2):77-87 [12031596.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2246-52 [12114427.001]
  • [Cites] Arch Pathol Lab Med. 2009 Mar;133(3):454-64 [19260750.001]
  • [Cites] J Clin Pathol. 2009 Apr;62(4):308-13 [19329710.001]
  • [Cites] FEBS J. 2009 Apr;276(8):2157-64 [19250312.001]
  • [Cites] J Neuropathol Exp Neurol. 2009 Apr;68(4):356-64 [19287316.001]
  • [Cites] Ann Surg Oncol. 2009 May;16(5):1378-83 [19224282.001]
  • [Cites] Free Radic Biol Med. 2009 May 1;46(9):1241-9 [19245828.001]
  • [Cites] Curr Mol Med. 2009 Apr;9(3):315-23 [19355913.001]
  • [Cites] Expert Rev Mol Diagn. 2009 Apr;9(3):243-57 [19379083.001]
  • [Cites] Methods Mol Biol. 2009;520:21-38 [19381945.001]
  • [Cites] Semin Cancer Biol. 2009 Jun;19(3):165-71 [19429480.001]
  • [Cites] FEBS Lett. 2009 Jun 5;583(11):1713-20 [19376112.001]
  • [Cites] Clin Cancer Res. 2009 Jun 1;15(11):3881-8 [19470736.001]
  • [Cites] Curr Alzheimer Res. 2009 Jun;6(3):196-204 [19519301.001]
  • [Cites] Nucleic Acids Res. 1997 Nov 1;25(21):4422-6 [9336479.001]
  • [Cites] Nucleic Acids Res. 1998 May 15;26(10):2255-64 [9580672.001]
  • [Cites] Anal Biochem. 1998 Nov 1;264(1):129-32 [9784198.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1141-5 [15734995.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4101-17 [15899800.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2788-94 [16675572.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1492-5 [16641902.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6111-7 [16778184.001]
  • [Cites] Clin Chem. 2006 Sep;52(9):1820-4 [16840584.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4262-9 [16908936.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1859-65 [16983705.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:235-43 [17108217.001]
  • [Cites] Cancer Biol Ther. 2006 Oct;5(10):1369-74 [16969071.001]
  • [Cites] FEBS Lett. 2007 Mar 6;581(5):795-9 [17289032.001]
  • [Cites] Life Sci. 2007 Apr 3;80(17):1608-18 [17343877.001]
  • [Cites] Anticancer Res. 2007 Mar-Apr;27(2):1207-12 [17465264.001]
  • [Cites] Nucleic Acids Res. 2007;35(9):2893-903 [17439964.001]
  • [Cites] J Neurosci Res. 2007 Jul;85(9):2006-16 [17469138.001]
  • [Cites] Oncol Rep. 2007 Aug;18(2):329-36 [17611652.001]
  • [Cites] Prostate. 2008 Jan 1;68(1):42-9 [18004747.001]
  • [Cites] J Urol. 2008 Jan;179(1):346-52 [18006010.001]
  • [Cites] Clin Neuropharmacol. 2008 Mar-Apr;31(2):104-19 [18382183.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2327-35 [18467724.001]
  • [Cites] PLoS One. 2008;3(7):e2698 [18628954.001]
  • [Cites] J Urol. 2009 Jul;182(1):324-9 [19447423.001]
  • (PMID = 20465502.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / R21RR024420; United States / NINDS NIH HHS / NS / R21NS060311; United States / NCRR NIH HHS / RR / R21 RR024420; United States / NINDS NIH HHS / NS / R21 NS060311-02; United States / NINDS NIH HHS / NS / R21 NS060311; United States / NCRR NIH HHS / RR / R21 RR024420-02; United States / NINDS NIH HHS / NS / NS060311-02; United States / NCRR NIH HHS / RR / RR024420-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 9007-49-2 / DNA
  • [Number-of-references] 83
  • [Other-IDs] NLM/ NIHMS229603; NLM/ PMC2933138
  •  go-up   go-down


40. Poizot-Martin I, Henry M, Benhaim S, Obry-Roguet V, Figarella D, Tamalet C: High level of HPV 16 and 18 DNA load in anal swabs from male and female HIV-1 infected patients. J Clin Virol; 2009 Apr;44(4):314-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High level of HPV 16 and 18 DNA load in anal swabs from male and female HIV-1 infected patients.
  • BACKGROUND: Despite HAART, the prevalence and incidence of anal cancer in HIV-infected individuals have increased.
  • Recently, the relationship between the severity of cervical lesions and oncogenic HPV load was demonstrated; however, few studies have assessed the level and the significance of oncogenic HPV load in patients at risk for anal neoplasia.
  • OBJECTIVES: To assess HPV genotypes and HPV 16/18 DNA load in HIV-1 infected patients at risk for anal neoplasia.
  • STUDY DESIGN: Cross-sectional pilot study from male and female HIV-1 infected individuals at risk for anal neoplasia in an outpatient HIV Clinical Unit of Marseilles university Hospitals.
  • RESULTS: Anal HPV was found in 79% of the patients whereas high-risk (HR) HPV types and infection with multiple HPV types were found in 83% and 61% of the patients, respectively.
  • CONCLUSIONS: Longitudinal studies are needed to evaluate the link between high anal HPV DNA load and progression to anal squamous intraepithelial lesions and anal cancer.
  • [MeSH-major] Anal Canal / virology. DNA, Viral / isolation & purification. HIV Infections / complications. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Papillomavirus Infections / epidemiology

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269245.001).
  • [ISSN] 1873-5967
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


41. Nattkemper TW, Wismüller A: Tumor feature visualization with unsupervised learning. Med Image Anal; 2005 Aug;9(4):344-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor feature visualization with unsupervised learning.
  • Dynamic contrast enhanced magnetic resonance imaging (DCE MRI) is applied for diagnosis and therapy control of breast cancer.
  • The technique is reported to characterize malignant tumors with high sensitivity and highly variable specificity.
  • Computer-based diagnosis (CAD) systems have been proposed to analyze and classify signal time curve data, extracted from hand selected ROI in the DCE MRI data.
  • In this paper, we apply the self-organizing map (SOM) to a set of time curve feature vectors of single voxels from seven benign lesions and seven malignant tumors.
  • Using the trained SOM, we are able to identify voxels with benign or malignant signal characteristics and to visualize lesion cross-sections with pseudo-colors.
  • [MeSH-major] Breast Neoplasms / pathology. Image Processing, Computer-Assisted / methods. Magnetic Resonance Imaging. Neural Networks (Computer)
  • [MeSH-minor] Contrast Media. Diagnosis, Computer-Assisted. Female. Gadolinium DTPA. Humans


42. Delikoukos S, Zacharoulis D, Hatzitheofilou C: Local posterior perianal block for proctologic surgery. Int Surg; 2006 Nov-Dec;91(6):348-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 72 patients with proctologic disorders consented to operation under LPPB for stapled hemorrhoidectomy, Milligan-Morgan hemorrhoidectomy, subanodermal fistula resection, perianal abscess revision, and anal tumor electrocoagulation.
  • [MeSH-major] Anus Diseases / surgery. Nerve Block
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / innervation. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17256435.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


43. Rossitto M, Pantè S, Manfrè A, Ciccolo A: [Post-operative analgesia in case of ano-rectal diseases]. Ann Ital Chir; 2009 Nov-Dec;80(6):459-61; discussion 461
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Post-operative analgesia in case of ano-rectal diseases].
  • [Transliterated title] L'analgesia post-operatoria nel trattamento delle patologie ano-rettali.
  • BACKGROUND: The aim of the study was that to evaluate the post-operative pain in case of ano-rectal diseases wether treated by ketorolac, or buprenorphine or tramadol.
  • MATERIALS AND METHODS: The intensity of post-operative pain was evaluated in 60 patients with hemorrhoidal diseases, fistulae, abscesses and anal neoplasms, divided into three homogenous groups and treated with intramuscular ketorolac (Group I), transdermal buprenorphine (Group II) and tramadol in elastomeric pump (Group III).
  • CONCLUSIONS: Better compliance and lower operating costs have given the preference to the use of transdermal buprenorphine for the treatment of diseases of the post-operative pain in the diseases of the anal canal.
  • [MeSH-minor] Adolescent. Adult. Aged. Analgesics, Opioid / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Anus Diseases / surgery. Buprenorphine / therapeutic use. Female. Humans. Ketorolac / therapeutic use. Male. Middle Aged. Tramadol / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20476679.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Anti-Inflammatory Agents, Non-Steroidal; 39J1LGJ30J / Tramadol; 40D3SCR4GZ / Buprenorphine; YZI5105V0L / Ketorolac
  •  go-up   go-down


44. Herat A, Whitfeld M, Hillman R: Anal intraepithelial neoplasia and anal cancer in dermatological practice. Australas J Dermatol; 2007 Aug;48(3):143-53; quiz 154-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia and anal cancer in dermatological practice.
  • Anal intraepithelial neoplasia is considered to be a precursor lesion of invasive anal cancer.
  • Human papillomaviruses are considered to be an important aetiological agent in both anal intraepithelial neoplasia and anal cancer.
  • Dermatologists are likely to encounter these conditions among the differential diagnoses to be considered in high-risk patients presenting with perianal and anal lesions.
  • Anal cancer rates are also increasing among the HIV-infected and HIV-non-infected population.
  • The successful treatment of anal intraepithelial neoplasia may reduce the risk of subsequent development of anal cancer.
  • However, current therapies for anal intraepithelial neoplasia may be associated with treatment-related morbidity and are not well validated.
  • It is currently not proven that they reduce the likelihood of the development of anal cancer.
  • Nevertheless, screening for anal intraepithelial neoplasia is being advocated for high-risk groups and may become standard dermatological care for these patients.
  • In view of recent developments in the understanding of this condition, this article reviews the current understanding of anal intraepithelial neoplasia and its treatment from a dermatological perspective.
  • [MeSH-major] Anus Neoplasms. Carcinoma in Situ. Carcinoma, Squamous Cell. Papillomavirus Infections
  • [MeSH-minor] Diagnosis, Differential. HIV Infections / complications. Humans. Papillomaviridae / pathogenicity

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680964.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 115
  •  go-up   go-down


45. Schwarz JK, Siegel BA, Dehdashti F, Myerson RJ, Fleshman JW, Grigsby PW: Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys; 2008 May 1;71(1):180-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer.
  • PURPOSE: To evaluate the response to therapy for anal carcinoma using post-therapy imaging with positron emission tomography (PET)/computed tomography and F-18 fluorodeoxyglucose (FDG) and to compare the metabolic response with patient outcome.
  • PATIENTS AND METHODS: This was a prospective cohort study of 53 consecutive patients with anal cancer.
  • Persistent abnormal FDG uptake (partial metabolic response) was found in the anal tumor in 9 patients.
  • The 2-year cause-specific survival rate was 94% for patients with a complete vs. 39% for patients with a partial metabolic response in the anal tumor (p = 0.0008).
  • The 2-year progression-free survival rate was 95% for patients with a complete vs. 22% for patients with a partial metabolic response in the anal tumor (p < 0.0001).
  • CONCLUSIONS: A partial metabolic response in the anal tumor as determined by post-therapy FDG-PET is predictive of significantly decreased progression-free and cause-specific survival after chemoradiotherapy for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Radiopharmaceuticals. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17996387.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


46. Vajdic CM, Anderson JS, Hillman RJ, Medley G, Grulich AE: Blind sampling is superior to anoscope guided sampling for screening for anal intraepithelial neoplasia. Sex Transm Infect; 2005 Oct;81(5):415-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blind sampling is superior to anoscope guided sampling for screening for anal intraepithelial neoplasia.
  • OBJECTIVES: Anal cytology smears are either collected "blind" (swab inserted 4 cm into anal canal and rotated) or guided through an anoscope (transformation zone visualised and then sampled).
  • CONCLUSIONS: Blind cytology smears are superior to anoscope guided smears for screening for anal neoplasia in homosexual men.
  • [MeSH-major] Anus Neoplasms / pathology. Homosexuality, Male. Proctoscopy / methods. Specimen Handling / methods

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1986 Sep 20;2(8508):657-60 [2876137.001]
  • [Cites] Sex Transm Infect. 1999 Jun;75(3):172-7 [10448395.001]
  • [Cites] Genitourin Med. 1988 Dec;64(6):378-82 [2852158.001]
  • [Cites] JAMA. 1990 Jun 6;263(21):2911-6 [2160023.001]
  • [Cites] Int J Cancer. 1990 Aug 15;46(2):203-6 [2166709.001]
  • [Cites] Int J Cancer. 1990 Aug 15;46(2):214-9 [2166710.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] Genitourin Med. 1991 Apr;67(2):92-8 [1851723.001]
  • [Cites] AIDS. 1993 Jan;7(1):43-9 [8382927.001]
  • [Cites] Sex Transm Dis. 1993 May-Jun;20(3):147-51 [8390103.001]
  • [Cites] Gastroenterology. 1993 Sep;105(3):658-66 [8359638.001]
  • [Cites] Genitourin Med. 1994 Feb;70(1):22-5 [8300094.001]
  • [Cites] AIDS. 1994 Mar;8(3):283-95 [8031509.001]
  • [Cites] Br J Surg. 1995 Apr;82(4):473-4 [7613888.001]
  • [Cites] Mod Pathol. 1995 Apr;8(3):270-4 [7617653.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Obstet Gynecol. 2002 Jun;99(6):1053-9 [12052599.001]
  • [Cites] Obstet Gynecol. 2003 Aug;102(2):266-72 [12907098.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):915-20 [15220697.001]
  • [Cites] Br J Vener Dis. 1984 Jun;60(3):205 [6329409.001]
  • [Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]
  • [Cites] Acta Cytol. 1997 Jul-Aug;41(4):1167-70 [9250316.001]
  • [Cites] Cytopathology. 1998 Feb;9(1):15-22 [9523124.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]
  • [Cites] J Infect Dis. 1998 Jul;178(1):45-52 [9652422.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • (PMID = 16199742.001).
  • [ISSN] 1368-4973
  • [Journal-full-title] Sexually transmitted infections
  • [ISO-abbreviation] Sex Transm Infect
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1745038
  •  go-up   go-down


47. Soumarová R, Homola L, Perková H, Czudek S, Skrovina M, Adamcík L: [The role of interstitial brachytherapy in multimodality management of solid tumors]. Rozhl Chir; 2007 Oct;86(10):533-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of interstitial brachytherapy in multimodality management of solid tumors].
  • Its prons include, in particular, a possibility to apply a dose, in addition to external radiotherapy, directly into the tumor region or its focus, which may improve treatment success rates in patients with localized tumors.
  • The commonest diagnoses, where interstitial brachytherapy is employed, include the following: breast carcinomas, soft tissue sarcomas, head and neck tumors, gynaecological tumors, penile and anal tumors and prostate tumors.
  • [MeSH-major] Brachytherapy. Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064791.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 54
  •  go-up   go-down


48. Abramowitz L, Benabderrahmane D, Baron G, Walker F, Yeni P, Duval X: Systematic evaluation and description of anal pathology in HIV-infected patients during the HAART era. Dis Colon Rectum; 2009 Jun;52(6):1130-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systematic evaluation and description of anal pathology in HIV-infected patients during the HAART era.
  • PURPOSE: This study aimed to determine the prevalence of macroscopic anal lesions and associated factors in HIV-infected outpatients during the era of highly active antiretroviral therapy.
  • METHODS: A randomly selected sample of patients with HIV-infection receiving follow-up care in the infectious diseases department of Bichat University Hospital was invited to participate in a systematic screening program consisting of anal examination with anoscopy and a standardized questionnaire.
  • Overall, 208 patients (44 percent) had at least one anal macroscopic lesion: 108 patients (22.8 percent) had human papilloma (HPV)-related lesions (condyloma with or without dysplasia), 67 (14.2 percent) had hemorrhoidal disease, 50 (10.6 percent) had anal fissures, and 44 (9.3) percent had other anal lesions.
  • Independent significantly associated factors for anal condyloma were history of anal condyloma (OR, 2.09) and median number of episodes of sexual intercourse per month (OR, 1.03) in men who have sex with men; history of genital condyloma (OR, 26.74), and unprotected sexual intercourse (OR, 7.47) in heterosexual men; and CD4 cell count below 200/mm3 (OR, 6.02), receptive anal intercourse (OR, 6.37), and history of anal condyloma (OR, 16.69) in women.
  • Neither sexual behavior nor characteristics related to HIV infection were associated with hemorrhoidal disease or anal fissure.
  • CONCLUSIONS: Because patients with HIV infections have a high prevalence of unreported anal lesions that may be highly contagious, involve risk of anal neoplasia, or negatively affect quality of life, systematic anal screening should be conducted in the HIV-infected population.
  • [MeSH-major] Anus Diseases / epidemiology. HIV Infections / complications


49. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, Kuznetsova NP, Vlassov VV, Laktionov PP: Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer; 2006 May 22;94(10):1492-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation.
  • Tumour development is characterised by the increased circulating DNA (cirDNA) concentration and by tumour-related changes in blood plasma DNA.
  • Tumour development was shown to lead to significant changes in the distribution of cirDNA between cell-free and cell-surface-bound fractions.
  • Analysis of RARbeta2 and RASSF1A methylation in the total cirDNA provides 95% diagnostic coverage in breast cancer patients, 60% in patients with benign lesions, and is without false-positive results in healthy women.
  • Results of the study indicate that methylation-specific PCR of RARbeta2 and RASSF1A genes based on the total cirDNA combined with the quantitative analysis of cirDNA distribution between cell-bound and cell-free fractions in blood provide the sensitive and accurate detection and discrimination of malignant and benign breast tumours.
  • [MeSH-major] Breast Neoplasms / blood. DNA Methylation. DNA, Neoplasm / blood. DNA-Binding Proteins / genetics. Fibroadenoma / blood. Receptors, Retinoic Acid / genetics. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2000 Apr;906:5-7 [10818586.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:191-6 [17108211.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):71-6 [11829433.001]
  • [Cites] Anticancer Drugs. 2002 Apr;13(4):353-7 [11984080.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5462-82 [12154408.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):149-52 [12455027.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:217-20 [15251963.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:221-7 [15251964.001]
  • [Cites] Anal Biochem. 1980 Mar 1;102(2):344-52 [6158890.001]
  • [Cites] J Clin Invest. 1985 Dec;76(6):2182-90 [3001145.001]
  • [Cites] Mol Biol (Mosk). 1988 Nov-Dec;22(6):1667-72 [3252155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Nucleic Acids Res. 1999 Jun 1;27(11):2315-24 [10325420.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3956-63 [10339505.001]
  • [Cites] Histol Histopathol. 1999 Oct;14(4):1159-64 [10506932.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(6-7):873-7 [15560075.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):389-94 [10956415.001]
  • (PMID = 16641902.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / HIC1 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta
  • [Other-IDs] NLM/ PMC2361269
  •  go-up   go-down


50. Bullitt E, Zeng D, Gerig G, Aylward S, Joshi S, Smith JK, Lin W, Ewend MG: Vessel tortuosity and brain tumor malignancy: a blinded study. Acad Radiol; 2005 Oct;12(10):1232-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vessel tortuosity and brain tumor malignancy: a blinded study.
  • Characteristic vessel tortuosity abnormalities appear early during tumor development, affect initially healthy vessels, spread beyond the confines of tumor margins, and do not simply mirror tissue perfusion.
  • The ability to detect and quantify tortuosity abnormalities on high-resolution magnetic resonance angiography (MRA) images offers a new approach to the noninvasive diagnosis of malignancy.
  • MATERIALS AND METHODS: The regional vasculature of 34 healthy subjects was compared with the tumor-associated vasculature of 30 brain tumors before surgical resection.
  • The operator performing the analysis was blinded to the diagnosis.
  • Vessels were segmented from an MRA of each subject, a region of interest was defined in each tumor patient and was mapped to all healthy controls, and a statistical analysis of vessel shape measures was then performed over the region of interest.
  • Many difficult cases were included, such as pinpoint, hemorrhagic, and irradiated tumors, as were hypervascular benign tumors.
  • Tumors were identified as benign or malignant on the basis of histological evaluation.
  • RESULTS: A discriminant analysis performed at the study's conclusion successfully classified all but one of the 30 tumors as benign or malignant on the basis of vessel tortuosity.
  • CONCLUSIONS: Quantitative, statistical measures of vessel shape offer a new approach to the diagnosis and staging of disease.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acad Radiol. 2003 Dec;10(12):1341-8 [14697002.001]
  • [Cites] Int J Mol Med. 2002 Mar;9(3):299-310 [11836637.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] Neuroradiology. 2001 May;43(5):345-52 [11396737.001]
  • [Cites] Brain Tumor Pathol. 2000;17(3):111-20 [11310918.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3683-8 [10919633.001]
  • [Cites] Cancer Biother Radiopharm. 1999 Feb;14(1):31-6 [10850285.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):143-7 [10639516.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):94-5 [10639502.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Sep;22(9):1163-71 [12956271.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1284-91 [11948144.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] Med Image Anal. 2005 Feb;9(1):39-49 [15581811.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):585-90 [15560716.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):577-84 [15560715.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1969 Apr;105(4):795-805 [4308528.001]
  • [Cites] IEEE Trans Med Imaging. 2002 Feb;21(2):61-75 [11929106.001]
  • (PMID = 16179200.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219-07; United States / NIBIB NIH HHS / EB / R01 EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219; United States / NIBIB NIH HHS / EB / EB000219-07
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS53777; NLM/ PMC2517122
  •  go-up   go-down


51. Schlecht HP, Fugelso DK, Murphy RK, Wagner KT, Doweiko JP, Proper J, Dezube BJ, Panther LA: Frequency of occult high-grade squamous intraepithelial neoplasia and invasive cancer within anal condylomata in men who have sex with men. Clin Infect Dis; 2010 Jul 1;51(1):107-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of occult high-grade squamous intraepithelial neoplasia and invasive cancer within anal condylomata in men who have sex with men.
  • Human papillomavirus causes anal condylomata, high-grade anal intraepithelial neoplasia, and anal squamous cell cancer.
  • We found high-grade intraepithelial neoplasia or squamous cell cancer in 75 (47%) of 159 HIV-seropositive men who have sex with men (MSM) and in 42 (26%) of 160 HIV-seronegative MSM with anal condylomata meriting surgery (P<.001, determined by use of the chi(2) test).
  • Anal condylomata in MSM often harbor high-grade intraepithelial neoplasia and squamous cell cancer.
  • [MeSH-major] Anus Diseases / complications. Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology. Condylomata Acuminata / complications. Homosexuality, Male. Papillomavirus Infections / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Alphapapillomavirus. Cohort Studies. HIV Seronegativity. HIV Seropositivity / complications. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Young Adult


52. Tsai BM, Finne CO, Nordenstam JF, Christoforidis D, Madoff RD, Mellgren A: Transanal endoscopic microsurgery resection of rectal tumors: outcomes and recommendations. Dis Colon Rectum; 2010 Jan;53(1):16-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery resection of rectal tumors: outcomes and recommendations.
  • PURPOSE: Transanal endoscopic microsurgery provides a minimally invasive alternative to radical surgery for excision of benign and malignant rectal tumors.
  • We analyzed patient and operative factors, complications, and tumor recurrence.
  • RESULTS: Two hundred sixty-nine patients underwent transanal endoscopic microsurgery for benign (n = 158) and malignant (n = 111) tumors.
  • Local recurrence rates for 121 benign and 83 malignant tumors were 5% for adenomas, 9.8% for T1 adenocarcinoma, 23.5% for T2 adenocarcinoma, 100% for T3 adenocarcinoma, and 0% for carcinoid tumors.
  • CONCLUSIONS: Transanal endoscopic microsurgery is a safe and effective method for excision of benign and malignant rectal tumors.
  • Transanal endoscopic microsurgery can be offered for (1) curative resection of benign tumors, carcinoid tumors, and select T1 adenocarcinomas, (2) histopathologic staging in indeterminate cases, and (3) palliative resection in patients medically unfit or unwilling to undergo radical resection.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Colectomy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Microsurgery. Middle Aged. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010345.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Hadar T, Shvero J, Yaniv E, Shvili I, Leabu M, Koren R: Human topoisomerase II-alpha is highly expressed in sinonasal-inverted papilloma, but not in inflammatory polyp. J Cell Mol Med; 2008 Sep-Oct;12(5A):1551-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sinonasal-inverted papilloma is a benign tumour with a high rate of recurrence, but possible malignant transformation.
  • Therefore, investigation of predisposition to malignant transformation of sinonasal-inverted papilloma gives clinicians the opportunity for adequate treatment.
  • These results suggest that the inverte papilloma contains a significantly higher cell population with proliferative activity by comparison with normal sinonasal and inflammatory polyp epithelia, showing a significant correlation between topoII-alpha and Ki67 expression, and indicating that topoII-alpha could be a independent prognostic factor for a putative malignant transformation.
  • [MeSH-major] Antigens, Neoplasm / metabolism. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Nose Neoplasms / enzymology. Nose Neoplasms / pathology. Papilloma, Inverted / enzymology. Papilloma, Inverted / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18544048.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC3918071
  •  go-up   go-down


54. Davoren PA, McNeill RE, Lowery AJ, Kerin MJ, Miller N: Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer. BMC Mol Biol; 2008;9:76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The discovery that aberrant expression of specific miRNAs contributes to human disease has fueled much interest in profiling the expression of these molecules.
  • A universal endogenous control suitable for every tissue type, treatment and disease stage has not been identified and is unlikely to exist, so, to avoid introducing further error in the quantification of expression data it is necessary that candidate ECs be validated in the samples of interest.
  • In this study, the expression of five miRNA genes (let-7a, miR-10b, miR-16, miR-21 and miR-26b) and three small nucleolar RNA genes (RNU19, RNU48 and Z30) was examined across malignant, benign and normal breast tissues to determine the most appropriate normalisation strategy.
  • [MeSH-major] Breast Neoplasms / genetics. Gene Expression Profiling / standards. Gene Expression Regulation, Neoplastic. MicroRNAs / genetics
  • [MeSH-minor] Female. Gene Silencing. Genes, Neoplasm. Humans. Polymerase Chain Reaction / standards. RNA, Small Nuclear / genetics. Reference Standards

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2005 Dec 15;14(24):3813-21 [16239240.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] Nucleic Acids Res. 2006;34(2):e9 [16434699.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 28;343(1):85-9 [16529715.001]
  • [Cites] J Urol. 2006 May;175(5):1915-20 [16600798.001]
  • [Cites] Mol Cancer. 2006;5:24 [16784538.001]
  • [Cites] Oncogene. 2006 Oct 9;25(46):6188-96 [17028598.001]
  • [Cites] Cell. 2006 Nov 17;127(4):679-95 [17110329.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(5):1859-67 [17194750.001]
  • [Cites] Am J Obstet Gynecol. 2007 Mar;196(3):261.e1-6 [17346547.001]
  • [Cites] Nat Protoc. 2006;1(3):1559-82 [17406449.001]
  • [Cites] BMC Genomics. 2007;8:166 [17565689.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Nov 23;363(3):542-6 [17889832.001]
  • [Cites] Nature. 2007 Oct 11;449(7163):682-8 [17898713.001]
  • [Cites] Nature. 2008 Jan 10;451(7175):147-52 [18185580.001]
  • [Cites] BMC Mol Biol. 2007;8:107 [18042273.001]
  • [Cites] Nat Cell Biol. 2008 Feb;10(2):202-10 [18193036.001]
  • [Cites] Breast Cancer Res. 2007;9(6):R76 [17980029.001]
  • [Cites] Hepatology. 2008 Mar;47(3):897-907 [18176954.001]
  • [Cites] RNA. 2008 May;14(5):844-52 [18375788.001]
  • [Cites] J Biol Chem. 2000 May 5;275(18):13967-73 [10788523.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] J Biochem Biophys Methods. 2000 Nov 20;46(1-2):69-81 [11086195.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14311-6 [11106375.001]
  • [Cites] EMBO Rep. 2001 Nov;2(11):986-91 [11713189.001]
  • [Cites] Hum Mol Genet. 2001 Nov 1;10(23):2687-700 [11726556.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):894-902 [11842100.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(19):6663-8 [12215523.001]
  • [Cites] Anal Biochem. 2002 Oct 15;309(2):293-300 [12413463.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Cancer Lett. 2003 Mar 20;192(1):1-17 [12637148.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Bioessays. 2003 Oct;25(10):930-9 [14505360.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D109-11 [14681370.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 [14973191.001]
  • [Cites] Genome Biol. 2004;5(3):R13 [15003116.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9740-4 [15210942.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5245-50 [15289330.001]
  • [Cites] J Biomol Tech. 2004 Sep;15(3):155-66 [15331581.001]
  • [Cites] Genome Biol. 2004;5(9):R68 [15345052.001]
  • [Cites] In Vitro Cell Dev Biol. 1987 Aug;23(8):585-90 [3114226.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5616-9 [3664468.001]
  • [Cites] Cell. 1993 Dec 3;75(5):843-54 [8252621.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1391-400 [8657112.001]
  • [Cites] BMC Dev Biol. 2005;5:27 [16324220.001]
  • [Cites] Cell. 1997 May 30;89(5):799-809 [9182768.001]
  • [Cites] Nucleic Acids Res. 1998 Apr 1;26(7):1576-87 [9512526.001]
  • [Cites] RNA. 1998 Apr;4(4):445-54 [9630250.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6906-17 [10490628.001]
  • [Cites] Anal Biochem. 2004 Dec 1;335(1):1-9 [15519565.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6029-33 [16024602.001]
  • [Cites] Biotechniques. 2005 Jul;39(1):75-85 [16060372.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7376-83 [16243810.001]
  • [Cites] RNA. 2005 Nov;11(11):1737-44 [16244135.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • (PMID = 18718003.001).
  • [ISSN] 1471-2199
  • [Journal-full-title] BMC molecular biology
  • [ISO-abbreviation] BMC Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / RNA, Small Nuclear
  • [Other-IDs] NLM/ PMC2533012
  •  go-up   go-down


55. Palefsky J: Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS; 2009 Jan;4(1):52-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus-related disease in people with HIV.
  • This review will describe recent findings in HPV-associated cancer incidence since the introduction of antiretroviral therapy, HPV/disease prevalence at sites other than cervix and anus, and recent data on screening and treatment of anal intraepithelial neoplasia.
  • RECENT FINDINGS: Consistent with high prevalence of anogenital HPV infection, new data on cervical intraepithelial neoplasia and anal intraepithelial neoplasia in HIV-positive men and women show that the incidence of cervical cancer has not declined since the introduction of antiretroviral therapy and that the incidence of anal cancer is rising.
  • Several studies also highlight high rates of HPV infection and HPV-associated disease at sites other than the cervix and anus, including the penis and the mouth.
  • Treatment methods for anal intraepithelial neoplasia have been described and show reasonable efficacy.
  • SUMMARY: New data imply that the problem of HPV-related cancers will not decline among HIV-positive men and women in the antiretroviral therapy era, highlighting the need to perform studies to determine if screening and treatment of anal intraepithelial neoplasia will prevent development of anal cancer.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Mar 15;88(6):1464-9 [10717631.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):491-9 [18614927.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]
  • [Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):915-20 [15220697.001]
  • [Cites] J Invest Dermatol. 2008 Aug;128(8):2078-83 [18273049.001]
  • [Cites] J Invest Dermatol. 2008 Sep;128(9):2316-24 [18385760.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2008 Sep;140(1):103-7 [18472205.001]
  • [Cites] J Oral Pathol Med. 2008 Oct;37(9):555-9 [18355174.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):143-50 [17354235.001]
  • [Cites] N Engl J Med. 2007 May 10;356(19):1944-56 [17494927.001]
  • [Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] Int J STD AIDS. 2007 Aug;18(8):538-42 [17686215.001]
  • [Cites] Br J Dermatol. 2007 Sep;157(3):523-30 [17573882.001]
  • [Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]
  • [Cites] Sex Transm Dis. 2008 Feb;35(2):197-202 [18216727.001]
  • [Cites] Int J STD AIDS. 2008 Feb;19(2):118-20 [18334066.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):407-20 [18334711.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]
  • [Cites] Curr HIV/AIDS Rep. 2008 May;5(2):78-85 [18510893.001]
  • [Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]
  • [Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]
  • [Cites] Int J STD AIDS. 2008 Jul;19(7):445-9 [18574114.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • (PMID = 19339939.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA054053-08; United States / NCI NIH HHS / CA / R01 CA054053; United States / NCI NIH HHS / CA / R01 CA088739; United States / NCI NIH HHS / CA / R01 CA054053-08; United States / NCI NIH HHS / CA / R01 CA088739-03; United States / NCI NIH HHS / CA / CA088739-03
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  • [Number-of-references] 36
  • [Other-IDs] NLM/ NIHMS94538; NLM/ PMC2756707
  •  go-up   go-down


56. Rehnberg J, Zendehrokh N, Dejmek A: Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions. Anal Quant Cytol Histol; 2007 Aug;29(4):217-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions.
  • OBJECTIVE: To determine the proliferation rates of mesothelial cells in metastatic and benign effusions.
  • STUDY DESIGN: Immunohistochemistry was performed on formalin-fixed pellets from 16 malignant and 9 benign clinical effusions.
  • Dual staining with antibodies against Ki-67 (MIB-1) and desmin was applied to all effusions to differentiate between benign mesothelial cells and malignant cells, and the proportions of desmin+/Ki-67+ and desmin+/Ki-67- cells were calculated.
  • RESULTS: In 7 malignant effusions no proliferating mesothelial cells were found, whereas some rate of proliferation could always be demonstrated in mesothelial cells in the benign effusions.
  • Further, the median proportions of proliferating cells, malignant 2% vs. benign 11%, differed significantly.
  • CONCLUSIONS: To our knowledge this finding has not been previously described, and it may have implications for both cytologic diagnosis and the understanding of tumor biology and the interaction between tumor cells and mesothelial cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879629.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin; 0 / Ki-67 Antigen
  •  go-up   go-down


57. Lanteri R, Aliotta I, Racalbuto A, Licata A: Anal GIST in older old patient: a case report. G Chir; 2005 Apr;26(4):135-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal GIST in older old patient: a case report.
  • It is generally difficult to determine if they are to be considered as a benign or malignant neoplastic disease.
  • We present the case of a patient with recurrence of anal GIST who was examined 8 years after the first treatment.
  • During rectal exploration we found a mass spreading inside the lumen 3 cm from the anal verge.
  • Colonoscopy showed that the tumour, which was 7 x 5 cm in size, was inside the wall with normal mucosa.
  • The patient was discharged 5 days after surgery and is alive; she only showed a small local recurrence of disease 30 months after treatment.
  • Histological examination confirmed that the tumour was a GIST This case provides the basis for a discussion about characteristics and the evolution of this group of pathologies.
  • [MeSH-major] Anus Neoplasms / surgery. Gastrointestinal Stromal Tumors / surgery. Neoplasm Recurrence, Local
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16035248.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


58. Laughney AM, Krishnaswamy V, Garcia-Allende PB, Conde OM, Wells WA, Paulsen KD, Pogue BW: Automated classification of breast pathology using local measures of broadband reflectance. J Biomed Opt; 2010 Nov-Dec;15(6):066019
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We demonstrate that morphological features pertinent to a tissue's pathology may be ascertained from localized measures of broadband reflectance, with a mesoscopic resolution (100-μm lateral spot size) that permits scanning of an entire margin for residual disease.
  • The technical aspects and optimization of a k-nearest neighbor classifier for automated diagnosis of pathologies are presented, and its efficacy is validated in 29 breast tissue specimens.
  • When discriminating between benign and malignant pathologies, a sensitivity and specificity of 91 and 77% was achieved.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Jul 6;406(6791):35-6 [10894529.001]
  • [Cites] J Biomed Opt. 2010 Jul-Aug;15(4):047001 [20799832.001]
  • [Cites] J Biomed Opt. 2000 Apr;5(2):221-8 [10938787.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):656-64 [11034242.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1620-9 [11375944.001]
  • [Cites] Am J Obstet Gynecol. 2002 Mar;186(3):374-82 [11904594.001]
  • [Cites] Semin Diagn Pathol. 2002 Nov;19(4):207-18 [12469788.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1681-92 [12655525.001]
  • [Cites] IEEE Trans Biomed Eng. 2003 Nov;50(11):1233-42 [14619993.001]
  • [Cites] Ann Surg Oncol. 2004 Jan;11(1):65-70 [14699036.001]
  • [Cites] Appl Opt. 2004 May 20;43(15):3048-54 [15176191.001]
  • [Cites] Opt Lett. 2004 May 15;29(10):1087-9 [15181994.001]
  • [Cites] Arch Pathol Lab Med. 1987 Jun;111(6):514-7 [3555403.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):747-53 [2777664.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):356-63 [1445509.001]
  • [Cites] Arch Surg. 1994 Sep;129(9):952-6; discussion 956-7 [8080378.001]
  • [Cites] Anal Chem. 1995 Mar 1;67(5):777-83 [7762814.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):259-67 [8625101.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2189-92 [8635082.001]
  • [Cites] Phys Med Biol. 1997 May;42(5):803-14 [9172260.001]
  • [Cites] Photochem Photobiol. 1998 Jul;68(1):123-32 [9679458.001]
  • [Cites] JAMA. 2005 Feb 23;293(8):964-9 [15728167.001]
  • [Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]
  • [Cites] Phys Med Biol. 2005 Jun 7;50(11):2573-81 [15901955.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):051704 [16292956.001]
  • [Cites] Arch Pathol Lab Med. 2005 Dec;129(12):1565-74 [16329729.001]
  • [Cites] Breast J. 2006 Mar-Apr;12(2):150-3 [16509840.001]
  • [Cites] J Biomed Opt. 2006 Jul-Aug;11(4):041106 [16965134.001]
  • [Cites] J Biomed Opt. 2006 Nov-Dec;11(6):064007 [17212530.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1458-71 [17260108.001]
  • [Cites] J Biomed Opt. 2008 May-Jun;13(3):034015 [18601560.001]
  • [Cites] Eur J Surg Oncol. 2009 Jan;35(1):32-7 [18539425.001]
  • [Cites] J Biomed Opt. 2009 Jan-Feb;14(1):014004 [19256692.001]
  • [Cites] Langenbecks Arch Surg. 2009 Jul;394(4):591-609 [18781322.001]
  • [Cites] J Biomed Opt. 2009 May-Jun;14(3):034034 [19566327.001]
  • [Cites] Ann Surg Oncol. 2009 Oct;16(10):2717-30 [19609829.001]
  • [Cites] Am J Surg. 2009 Oct;198(4):566-74 [19800470.001]
  • [Cites] Lasers Surg Med. 2010 Jan;42(1):15-23 [20077490.001]
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1058-67 [10935646.001]
  • (PMID = 21198193.001).
  • [ISSN] 1560-2281
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA080139; United States / NCI NIH HHS / CA / P01 CA80139
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3032233
  •  go-up   go-down


59. Levman J, Leung T, Causer P, Plewes D, Martel AL: Classification of dynamic contrast-enhanced magnetic resonance breast lesions by support vector machines. IEEE Trans Med Imaging; 2008 May;27(5):688-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early detection of breast cancer is one of the most important factors in determining prognosis for women with malignant tumors.
  • Computer-aided diagnosis (CAD) systems have the potential to assist radiologists in the early detection of cancer.
  • A key component of the development of such a CAD system will be the selection of an appropriate classification function responsible for separating malignant and benign lesions.
  • The purpose of this study is to evaluate the effects of variations in temporal feature vectors and kernel functions on the separation of malignant and benign DCE-MRI breast lesions by support vector machines (SVMs).

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IEEE Trans Med Imaging. 2002 Dec;21(12):1552-63 [12588039.001]
  • [Cites] Acad Radiol. 2003 Feb;10(2):189-97 [12583571.001]
  • [Cites] Radiology. 2003 Oct;229(1):225-32 [14519877.001]
  • [Cites] Med Phys. 2003 Sep;30(9):2350-9 [14528957.001]
  • [Cites] Med Phys. 2004 May;31(5):1076-82 [15191295.001]
  • [Cites] JAMA. 2004 Sep 15;292(11):1317-25 [15367553.001]
  • [Cites] Magn Reson Med. 1998 Jan;39(1):108-15 [9438444.001]
  • [Cites] Am J Hum Genet. 1998 Mar;62(3):676-89 [9497246.001]
  • [Cites] Med Phys. 1998 Sep;25(9):1647-54 [9775369.001]
  • [Cites] Acad Radiol. 2004 Dec;11(12):1344-54 [15596372.001]
  • [Cites] Bioinformatics. 2005 Feb 15;21(4):439-44 [15608050.001]
  • [Cites] Artif Intell Med. 2005 Jun;34(2):129-39 [15894177.001]
  • [Cites] Med Image Anal. 2005 Aug;9(4):344-51 [15907392.001]
  • [Cites] Med Image Comput Comput Assist Interv. 2006;9(Pt 2):686-93 [17354832.001]
  • [Cites] Magn Reson Med. 1999 Jan;41(1):124-31 [10025619.001]
  • [Cites] Magn Reson Imaging. 2001 Jan;19(1):51-7 [11295347.001]
  • [Cites] Semin Roentgenol. 2001 Jul;36(3):238-49 [11475070.001]
  • [Cites] Magn Reson Imaging. 2002 Feb;20(2):147-54 [12034335.001]
  • [Cites] AJR Am J Roentgenol. 2002 Nov;179(5):1193-9 [12388497.001]
  • [Cites] Physiol Meas. 2002 Nov;23(4):727-39 [12450272.001]
  • [Cites] J Magn Reson Imaging. 2003 Mar;17(3):337-42 [12594724.001]
  • (PMID = 18450541.001).
  • [ISSN] 1558-254X
  • [Journal-full-title] IEEE transactions on medical imaging
  • [ISO-abbreviation] IEEE Trans Med Imaging
  • [Language] ENG
  • [Grant] None / None / / 67225; Canada / Canadian Institutes of Health Research / / 67225
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Other-IDs] NLM/ CAMS1120; NLM/ PMC2891012
  •  go-up   go-down


60. Reschner A, Harlin H, Laven B, Eriksson F, Pisa P, Egevad L: Expression of immunomodulating genes in prostate cancer and benign prostatic tissue. Anal Quant Cytol Histol; 2009 Apr;31(2):74-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of immunomodulating genes in prostate cancer and benign prostatic tissue.
  • OBJECTIVE: To investigate the expression of immunomodulating genes in prostate cancer and benign prostatic tissue.
  • STUDY DESIGN: We investigated by quantitative real-time polymerase chain reaction the expression of indoleamine 2,3-dioxygenase, arginase 1, arginase 2, inducible form of nitric oxide synthase, cyclooxygenase 2 (COX-2), programmed death ligand 1 and interleukin 10 in 36 matched pairs of samples from prostate cancer and benign prostatic tissue.
  • RESULTS: Among the genes analyzed, arginase 2 and COX-2 showed statistically significant up-regulation and down-regulation, respectively, in malignant compared to benign prostate tissue.
  • In addition, arginase 1 was more often present in cancer than benign samples.
  • We provide a snapshot of immunosuppressive gene expression at the transcriptional level in the prostate tumor microenvironment.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19402383.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / CD274 protein, human; 0 / IL10 protein, human; 0 / Immunologic Factors; 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase; 130068-27-8 / Interleukin-10; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.5.3.1 / Arginase; EC 3.5.3.1 / arginase II, human
  •  go-up   go-down


61. Yili Z, Xiaoyan H, Hongwen D, Yun Z, Xin C, Peng W, Youmin G: The value of diffusion-weighted imaging in assessing the ADC changes of tissues adjacent to breast carcinoma. BMC Cancer; 2009;9:18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To define a threshold value of apparent diffusion coefficient (ADC) with which malignant breast lesions can be distinguished from benign lesions, and to evaluate the ADC change of peri-tumor tissue in breast carcinoma by echo planar-diffusion weighted imaging (EPI-DWI).
  • The ADC values were compared between malignant and benign lesions.
  • The ADC values of malignant lesion and layered peri-tumor tissues (from innermost layer 1 to outermost layer 4 with 5 mm every layer) in different directions were compared and the ADC values among different layers were compared.
  • RESULTS: The ADC value of 35 malignant lesions was statistically lower than that of 22 benign lesions (P < 0.05).
  • The ADC value of malignant lesions was statistically lower than that of peri-tumor tissues in different directions (P < 0.05).
  • For peri-tumor tissues, the ADC values increased gradually from layer 1 to layer 4 and there was a significant difference between the ADC values of layer 1 and layer 2 (P < 0.05); while from layer 2 outwards, there was no statistical difference among different layers.
  • CONCLUSION: ADC value was a sensitive and specific parameter that could help to differentiate benign and malignant breast lesions.
  • [MeSH-major] Breast Diseases / diagnosis. Breast Neoplasms / diagnosis. Echo-Planar Imaging / methods
  • [MeSH-minor] Adult. Aged. Breast / pathology. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Humans. Hyperplasia. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 23;338(3):1353-8 [16269133.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):644-9 [16163035.001]
  • [Cites] Breast J. 2006 Jan-Feb;12(1):28-36 [16409584.001]
  • [Cites] Cir Esp. 2006 Jan;79(1):3-9 [16426527.001]
  • [Cites] World J Gastroenterol. 2006 Mar 14;12(10):1626-9 [16570359.001]
  • [Cites] Anal Biochem. 2006 Aug 1;355(1):117-24 [16756932.001]
  • [Cites] Magn Reson Imaging. 2006 Sep;24(7):843-7 [16916701.001]
  • [Cites] J Magn Reson Imaging. 2006 Aug;24(2):319-24 [16786565.001]
  • [Cites] Breast J. 2006 Sep-Oct;12(5 Suppl 2):S174-80 [16958998.001]
  • [Cites] Gut. 2006 Nov;55(11):1598-605 [16682430.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2006 Aug;14(3):305-28, v [17098173.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6626-36 [17121881.001]
  • [Cites] Radiol Med. 2006 Dec;111(8):1124-33 [17171522.001]
  • [Cites] Histopathology. 2007 Jan;50(2):232-42 [17222252.001]
  • [Cites] Ai Zheng. 2007 Feb;26(2):168-71 [17298747.001]
  • [Cites] J Magn Reson Imaging. 2007 Jun;25(6):1101-12 [17520731.001]
  • [Cites] J Comput Assist Tomogr. 2007 May-Jun;31(3):449-54 [17538295.001]
  • [Cites] J Magn Reson Imaging. 2001 Mar;13(3):335-43 [11241804.001]
  • [Cites] Radiologe. 2002 Jan;42(1):1-5 [11930535.001]
  • [Cites] J Magn Reson Imaging. 2002 Aug;16(2):172-8 [12203765.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):926-33 [12569592.001]
  • [Cites] Br J Plast Surg. 2003 Jul;56(5):462-70 [12890459.001]
  • [Cites] Oncology (Williston Park). 2003 Nov;17(11):1511-33; discussion 1533-4, 1539, 1542 passim [14682107.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jan;130(1):39-44 [14732766.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2269-80 [15160329.001]
  • [Cites] Annu Rev Med. 1996;47:285-301 [8712782.001]
  • [Cites] Radiology. 2004 Dec;233(3):830-49 [15486214.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):1022-5 [15515012.001]
  • [Cites] Rofo. 2005 Jan;177(1):114-8 [15657829.001]
  • [Cites] Clin Breast Cancer. 2005 Feb;5(6):425-38 [15748463.001]
  • [Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]
  • [Cites] Magn Reson Med Sci. 2002 Jul 1;1(2):73-80 [16082129.001]
  • [Cites] Magn Reson Med Sci. 2004 Jul 15;3(2):79-85 [16093623.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Aug;5(4):737-45 [16111473.001]
  • [Cites] Magn Reson Med Sci. 2005;4(1):35-42 [16127252.001]
  • [Cites] Breast Cancer Res Treat. 2005 Dec;94(3):195-8 [16258704.001]
  • (PMID = 19144163.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2633008
  •  go-up   go-down


62. Driemel O, Kunkel M, Hullmann M, Kleinsasser N, Staudenmaier R, Müller-Richter U, Reichert TE, Kosmehl H: [Performance of conventional oral brush biopsies]. HNO; 2008 Feb;56(2):205-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytological assessment used well-established criteria of atypia to classify the specimen as either "tumor negative" (no signs of atypia, no malignant cells) or "tumor positive" (malignant cells, any sign of atypia or doubtful cells).
  • RESULTS: Despite a sufficient number of cells, a definite cytological diagnosis could not be established in six cases.
  • According to the criteria specified above, these specimens were classified as "tumor positive."
  • Seven out of 107 benign lesions were classified as false positive (specificity 93%).
  • Thus, this technique should not be used for diagnostic proof or to exclude malignant cells in a lesion suspicious for cancer.
  • However, oral brush biopsy provides a versatile back-up strategy to uncover the true nature of the disease if a lesion is clinically considered benign by mistake.
  • [MeSH-major] Biopsy / methods. Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Cell Pathol. 2003;25(3):139-46 [12775918.001]
  • [Cites] Mol Cancer. 2006 Mar 23;5:11 [16556320.001]
  • [Cites] Dtsch Zahnarztl Z. 1981 Nov;36(11):701-3 [6946905.001]
  • [Cites] Br J Oral Maxillofac Surg. 1996 Oct;34(5):461-6 [8909744.001]
  • [Cites] Dtsch Med Wochenschr. 1978 Jan 6;103(1):17-20 [620647.001]
  • [Cites] Br J Cancer. 2006 Apr 24;94(8):1170-5 [16622441.001]
  • [Cites] N Engl J Med. 2001 May 24;344(21):1603-7 [11372013.001]
  • [Cites] Mund Kiefer Gesichtschir. 2007 Jan;11(1):1-9 [17177045.001]
  • [Cites] J Am Dent Assoc. 1999 Oct;130(10):1445-57 [10570588.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1991 Jan;51(1):51-3 [2026300.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994 Nov;30B(6):405-8 [7536508.001]
  • [Cites] Dtsch Zahnarztl Z. 1981 Nov;36(11):697-700 [6946904.001]
  • [Cites] Ann Intern Med. 1949 Oct;31(4):661-74 [15392502.001]
  • [Cites] Int J Oral Maxillofac Surg. 2000 Dec;29(6):453-7 [11202330.001]
  • [Cites] Science. 1942 Apr 24;95(2469):438-9 [17842594.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):211-21 [11564897.001]
  • [Cites] Acta Cytol. 1963 Mar-Apr;7:107-10 [13978631.001]
  • [Cites] Oral Oncol. 2004 Sep;40(8):824-8 [15288838.001]
  • [Cites] Stomatol DDR. 1986 Dec;36(12):712-6 [2438824.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Apr;64(4):628-35 [16546642.001]
  • [Cites] J Oral Pathol Med. 2006 Jan;35(1):58-60 [16393256.001]
  • [Cites] J Dent Res. 1951 Jun;30(3):308-13 [14841304.001]
  • [Cites] Mund Kiefer Gesichtschir. 2006 Mar;10(2):89-93 [16485137.001]
  • [Cites] Cytopathology. 2007 Dec;18(6):348-55 [18031447.001]
  • [Cites] Br J Cancer. 1971 Mar;25(1):21-4 [5581297.001]
  • [Cites] APMIS. 2005 Mar;113(3):208-12 [15799765.001]
  • [Cites] J Oral Pathol Med. 2004 Aug;33(7):398-404 [15250831.001]
  • [Cites] Mund Kiefer Gesichtschir. 2002 Nov;6(6):410-4 [12447653.001]
  • [Cites] Gen Dent. 2000 Nov-Dec;48(6):656-60 [12004660.001]
  • [Cites] Head Neck. 2002 Mar;24(3):223-7 [11891953.001]
  • [Cites] Oral Oncol. 2002 Feb;38(2):125-30 [11854058.001]
  • [Cites] Int Dent J. 1968 Dec;18(4):708-23 [5252708.001]
  • [Cites] Oral Oncol. 2004 Sep;40(8):829-34 [15288839.001]
  • [Cites] Geburtshilfe Frauenheilkd. 1984 Aug;44(8):485-94 [6566637.001]
  • [Cites] J Indiana Dent Assoc. 2001 Summer;80(2):6-8 [11693004.001]
  • [Cites] Cytopathology. 1994 Feb;5(1):47-53 [8173031.001]
  • [Cites] Dtsch Zahnarztl Z. 1966 Jan 1;21(1):145-8 [5216203.001]
  • [Cites] Mund Kiefer Gesichtschir. 2004 Jul;8(4):229-36 [15293118.001]
  • (PMID = 18214406.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Wong AK, Chan RC, Aggarwal N, Singh MK, Nichols WS, Bose S: Human papillomavirus genotypes in anal intraepithelial neoplasia and anal carcinoma as detected in tissue biopsies. Mod Pathol; 2010 Jan;23(1):144-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus genotypes in anal intraepithelial neoplasia and anal carcinoma as detected in tissue biopsies.
  • Human papillomavirus (HPV) infection strongly correlates with the development of anal intraepithelial neoplasias and carcinomas; however, few studies have characterized the distribution of the specific subtypes of the virus in the varying grades of dysplasia.
  • This report characterizes the distribution of HPV 16/18 in surgical specimens with anal intraepithelial neoplasia (AIN) I-III and histological variants of anal carcinoma.
  • A total of 111 anal surgical specimens with no dysplasia (10), AIN I-III (53), and anal carcinomas (48) were evaluated for the presence of high-risk HPV infection and subtyped by nested PCR or the Invader Assay.
  • High-risk virus types were detected in progressively greater number of anal intraepithelial lesions from 56% in low grade to 88% in high grade.
  • The similarity in the prevalence of type 16 in high-grade dysplasia and squamous carcinomas suggests that anal intraepithelial lesion III is the true precursor of squamous carcinoma and warrants aggressive management.
  • Anal intraepithelial lesions II showed a virus distribution that was similar to low-grade dysplasia.
  • [MeSH-major] Anus Neoplasms / virology. Carcinoma in Situ / virology. Carcinoma, Squamous Cell / virology. Papillomavirus Infections / virology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Viral / analysis. Female. Genotype. Human papillomavirus 16 / genetics. Human papillomavirus 18 / genetics. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Prevalence. Young Adult

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838162.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


64. Garrison JB, Kyprianou N: Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res; 2006 Jan 1;66(1):464-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway.
  • In this study, the molecular events initiating this apoptotic effect were further investigated in vitro using the human androgen-independent prostate cancer cells PC-3 and the human benign prostate epithelial cells BPH-1.
  • These results show that doxazosin exerts its apoptotic effects against benign and malignant prostate cells via a death receptor-mediated mechanism with a potential integrin contribution towards cell survival outcomes.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Cell Dev Biol. 1999;15:269-90 [10611963.001]
  • [Cites] Cell Death Differ. 2005 Mar;12(3):233-42 [15665818.001]
  • [Cites] Cell Tissue Res. 2000 Jul;301(1):153-62 [10928288.001]
  • [Cites] J Cell Biol. 2001 Feb 5;152(3):633-43 [11157988.001]
  • [Cites] J Urol. 2003 Mar;169(3):1150-6 [12576871.001]
  • [Cites] J Urol. 2003 Apr;169(4):1520-5 [12629407.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):593-600 [12740905.001]
  • [Cites] Oncogene. 2003 May 8;22(18):2795-804 [12743602.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1615-21 [12771931.001]
  • [Cites] J Cell Physiol. 2003 Aug;196(2):386-93 [12811833.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37632-6 [12876280.001]
  • [Cites] J Med Chem. 2004 Aug 26;47(18):4453-62 [15317457.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] Cell. 1995 May 19;81(4):505-12 [7538907.001]
  • [Cites] Cell. 1996 Jun 14;85(6):817-27 [8681377.001]
  • [Cites] Nat Med. 1996 Dec;2(12):1361-6 [8946836.001]
  • [Cites] Curr Biol. 1996 Oct 1;6(10):1241-3 [8939562.001]
  • [Cites] J Natl Cancer Inst. 1997 Jun 4;89(11):783-9 [9182976.001]
  • [Cites] Cell Immunol. 1997 Aug 25;180(1):70-83 [9316641.001]
  • [Cites] Br J Urol. 1997 Oct;80(4):521-32 [9352686.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):76-83 [9426061.001]
  • [Cites] Prostate. 1998 Jul 1;36(2):92-101 [9655261.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5870-5 [9865748.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):963-72 [9815772.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):382-90 [9927051.001]
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):7987-92 [10075697.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Mar 24;256(3):603-7 [10080945.001]
  • [Cites] J Immunol. 1999 May 1;162(9):5205-11 [10227994.001]
  • [Cites] Cell Death Differ. 1999 May;6(5):394-401 [10381629.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):371-8 [10408840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8699-704 [10411938.001]
  • [Cites] Curr Biol. 1999 Sep 23;9(18):1043-6 [10508619.001]
  • [Cites] Curr Biol. 1999 Sep 23;9(18):1047-9 [10508612.001]
  • [Cites] Oncogene. 2001 Apr 5;20(15):1852-9 [11313933.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):319-27 [11803475.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):597-602 [11809715.001]
  • [Cites] Prostate. 2002 Apr 1;51(1):42-9 [11920957.001]
  • [Cites] Apoptosis. 2002 Jun;7(3):247-60 [11997669.001]
  • [Cites] Prostate. 2002 Jun 1;51(4):231-40 [11987151.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):296-300 [12124829.001]
  • [Cites] Anal Quant Cytol Histol. 2000 Feb;22(1):45-54 [10696460.001]
  • (PMID = 16397262.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107575; United States / NCI NIH HHS / CA / R01 CA107575-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adrenergic alpha-Antagonists; 0 / Antigens, CD95; 0 / FADD protein, human; 0 / Fas-Associated Death Domain Protein; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases; NW1291F1W8 / Doxazosin
  • [Other-IDs] NLM/ NIHMS19062; NLM/ PMC1850148
  •  go-up   go-down


65. Hessol NA, Holly EA, Efird JT, Minkoff H, Schowalter K, Darragh TM, Burk RD, Strickler HD, Greenblatt RM, Palefsky JM: Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women. AIDS; 2009 Jan 2;23(1):59-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women.
  • OBJECTIVES: To study anal intraepithelial neoplasia and its associations with anal and cervical human papillomavirus (HPV), cervical neoplasia, host immune status, and demographic and behavioral risk factors in women with and at risk for HIV infection.
  • METHODS: In 2001-2003 participants were interviewed, received a gynecological examination, anal and cervical cytology testing and, if abnormal, colposcopy-guided or anoscopy-guided biopsy of visible lesions.
  • Exfoliated cervical and anal specimens were assessed for HPV using PCR and type-specific HPV probing.
  • Logistic regression analyses were performed, and odds ratios (ORs) estimated risks for anal intraepithelial neoplasia.
  • Low-grade anal intraepithelial neoplasia was present in 12% of HIV-infected and 5% of HIV-uninfected women.
  • High-grade anal intraepithelial neoplasia was present in 9% of HIV-infected and 1% of HIV-uninfected women.
  • In adjusted analyses among HIV-infected women, the risk factors for low-grade anal intraepithelial neoplasia were younger age [OR = 0.59, 95% confidence interval (CI) = 0.36-0.97], history of receptive anal intercourse (OR = 3.2, 95% CI = 1.5-6.8), anal HPV (oncogenic types only OR = 11, 95% CI = 1.2-103; oncogenic and nononcogenic types OR = 11, 95% CI = 1.3-96), and cervical HPV (oncogenic and nononcogenic types OR = 3.5, 95% CI = 1.1-11).
  • In multivariable analyses among HIV-infected women, the only significant risk factor for high-grade anal intraepithelial neoplasia was anal HPV infection (oncogenic and nononcogenic types OR = 7.6, 95% CI = 1.5-38).
  • CONCLUSION: Even in the era of highly active antiviral therapy, the prevalence of anal intraepithelial neoplasia was 16% in HIV-infected women.
  • After controlling for potential confounders, several risk factors for low-grade anal intraepithelial neoplasia differed from risk factors for high-grade anal intraepithelial neoplasia.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Women and HIV .
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 16;86(22):1711-6 [7966400.001]
  • [Cites] Sex Transm Infect. 2005 Apr;81(2):142-6 [15800092.001]
  • [Cites] Lancet Oncol. 2005 Apr;6(4):204 [15830458.001]
  • [Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]
  • [Cites] Clin Diagn Lab Immunol. 2005 Sep;12(9):1013-9 [16148165.001]
  • [Cites] APMIS. 2007 Mar;115(3):195-203 [17367464.001]
  • [Cites] Lancet Oncol. 2007 Apr;8(4):311-6 [17395104.001]
  • [Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1107-14 [17548671.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):843-9 [11390533.001]
  • [Cites] Sex Transm Infect. 2001 Oct;77(5):327-31 [11588276.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2002 May;16(3):231-40 [12195562.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):94-100 [12838307.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):673-96, v [12852650.001]
  • [Cites] Biotechniques. 1995 Oct;19(4):566-8 [8777045.001]
  • [Cites] J Infect Dis. 1996 Oct;174(4):679-89 [8843203.001]
  • [Cites] Am J Epidemiol. 1996 Nov 15;144(10):916-23 [8916502.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 3;91(3):226-36 [10037100.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):708-15 [10218509.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] Lancet. 1991 Sep 14;338(8768):657-9 [1679474.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 May-Jun;2(3):223-8 [8318874.001]
  • [Cites] Obstet Gynecol. 1994 Feb;83(2):205-11 [8290181.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Expert Opin Pharmacother. 2004 Dec;5(12):2479-84 [15571466.001]
  • [Cites] Int J Cancer. 1996 Nov 27;68(5):559-64 [8938134.001]
  • [Cites] J Clin Microbiol. 1997 Jun;35(6):1304-10 [9163434.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] Epidemiology. 1998 Mar;9(2):117-25 [9504278.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] AIDS. 1998 Jul 9;12(10):1177-84 [9677167.001]
  • (PMID = 19050387.001).
  • [ISSN] 1473-5571
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / U01-AI-42590; United States / NIAID NIH HHS / AI / U01 AI031834; United States / NCI NIH HHS / CA / R01 CA 88739; United States / NIAID NIH HHS / AI / U01 AI035004; United States / NICHD NIH HHS / HD / U01-HD-32632; United States / NCI NIH HHS / CA / R01 CA088739; United States / NCRR NIH HHS / RR / UL1 RR024131; United States / NIAID NIH HHS / AI / U01 AI034989; United States / NIAID NIH HHS / AI / U01-AI-34994; United States / NIAID NIH HHS / AI / U01-AI-35004; United States / NCI NIH HHS / CA / CA088739-05S1; United States / NIAID NIH HHS / AI / U01-AI-31834; United States / NIAID NIH HHS / AI / U01 AI034994; United States / NIAID NIH HHS / AI / U01 AI034989-15; United States / NCI NIH HHS / CA / R01 CA088739-05S1; United States / NIAID NIH HHS / AI / U01-AI-34993; United States / NCI NIH HHS / CA / R01 CA085178; United States / NIAID NIH HHS / AI / U01 AI034993; United States / NIAID NIH HHS / AI / U01-AI-34989; United States / NICHD NIH HHS / HD / U01 HD032632; United States / NIAID NIH HHS / AI / U01 AI042590
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS84186; NLM/ PMC2614220
  •  go-up   go-down


66. Mikropoulos C, Williams T, Munthali L, Summers J: A rare case of anal tumor: Anal carcinosarcoma. World J Gastrointest Oncol; 2010 Dec 15;2(12):446-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of anal tumor: Anal carcinosarcoma.
  • Sarcomatoid carcinoma is a rare tumor with a poor prognosis, otherwise known as carcinosarcoma.
  • Gastrointestinal origin is very rare and only a limited number of anal carcinosarcomas have been reported in the literature.
  • The aim of this case report was to confirm that by combining treatment modalities we can achieve long disease free intervals.
  • Concomitant chemoradiotherapy led to a good partial response and this was followed by a consolidation surgical endo-anal excision.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2006 Mar 7;12(9):1481-4 [16552827.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Jun;18(6):748-9 [12753163.001]
  • [Cites] Hepatogastroenterology. 2000 Nov-Dec;47(36):1611-4 [11149014.001]
  • [Cites] Turk J Gastroenterol. 2006 Sep;17(3):236-9 [16941264.001]
  • [Cites] Histopathology. 1985 Sep;9(9):987-94 [2415439.001]
  • [Cites] Int Surg. 1979 Jan-Feb;64(1):13-9 [536139.001]
  • [Cites] Pathology. 2006 Jun;38(3):264-7 [16753754.001]
  • [Cites] Singapore Med J. 2008 Oct;49(10):e283-5 [18946600.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Semin Diagn Pathol. 1993 May;10(2):118-27 [8367621.001]
  • (PMID = 21191539.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3011099
  • [Keywords] NOTNLM ; Anal tumour / Carcinosarcoma / Chemoradiotherapy / Endo-anal excision / Spindle cell
  •  go-up   go-down


67. van Asten JJ, Cuijpers V, Hulsbergen-van de Kaa C, Soede-Huijbregts C, Witjes JA, Verhofstad A, Heerschap A: High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies. MAGMA; 2008 Nov;21(6):435-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Histopathology of prostate needle biopsies (PNBs) is an important part in the diagnosis, prognosis and treatment evaluation of prostate cancer.
  • Subsequent histopathology of the same biopsies classified the tissue either as cancer (n = 10) or benign (n = 30).
  • Significant metabolic differences were found between malignant and benign tissue using a small set of ratio's involving signals of choline compounds, citrate and lactate.
  • Moreover, significant correlations were observed between choline, total choline, and citrate over creatine signal ratios and the Gleason scores of tumor in PNBs and of tumor in the whole prostate.
  • [MeSH-major] Magnetic Resonance Spectroscopy / methods. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2001 Apr 6;494(1-2):112-6 [11297745.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3398-401 [9270004.001]
  • [Cites] Anticancer Res. 1997 May-Jun;17(3A):1455-60 [9179183.001]
  • [Cites] Magn Reson Med. 1993 Feb;29(2):149-57 [8429778.001]
  • [Cites] Magn Reson Med. 2006 Jun;55(6):1257-64 [16685733.001]
  • [Cites] Prostate. 1997 Mar 1;30(4):248-55 [9111602.001]
  • [Cites] Mol Cancer. 2006 May 15;5:17 [16700911.001]
  • [Cites] BJU Int. 2001 Jun;87(9):797-805 [11412216.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11270-5 [16837573.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jan;176(1):17-22 [11133530.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8927-30 [16982728.001]
  • [Cites] Prostate. 1997 Jun 1;31(4):264-81 [9180937.001]
  • [Cites] Expert Rev Mol Diagn. 2006 Nov;6(6):821-9 [17140369.001]
  • [Cites] Invest Radiol. 2007 Feb;42(2):116-22 [17220729.001]
  • [Cites] Magn Reson Med. 2001 Aug;46(2):213-8 [11477623.001]
  • [Cites] Magn Reson Med. 1993 Mar;29(3):285-91 [7680746.001]
  • [Cites] Radiol Clin North Am. 2000 Jan;38(1):115-38, viii-ix [10664669.001]
  • [Cites] Biochem Cell Biol. 1998;76(2-3):472-6 [9923716.001]
  • [Cites] NMR Biomed. 1999 Nov;12(7):413-39 [10654290.001]
  • [Cites] Magn Reson Med. 2003 Nov;50(5):944-54 [14587005.001]
  • [Cites] J Am Osteopath Assoc. 2006 Jan;106(1):23-7 [16428685.001]
  • [Cites] MAGMA. 2000 Jul;10(3):153-9 [10873205.001]
  • [Cites] Anal Bioanal Chem. 2004 Mar;378(6):1511-9 [15214411.001]
  • [Cites] Radiology. 2005 Mar;234(3):804-14 [15734935.001]
  • [Cites] J Urol. 1993 Dec;150(6):2019-24 [7693985.001]
  • [Cites] Urology. 1995 Mar;45(3):459-66 [7533458.001]
  • [Cites] J Magn Reson Imaging. 2002 Oct;16(4):451-63 [12353259.001]
  • [Cites] Magn Reson Med. 2003 Sep;50(3):627-32 [12939772.001]
  • [Cites] Magn Reson Med. 2003 Dec;50(6):1307-11 [14648580.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3030-4 [15833828.001]
  • (PMID = 19031091.001).
  • [ISSN] 0968-5243
  • [Journal-full-title] Magma (New York, N.Y.)
  • [ISO-abbreviation] MAGMA
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] AYI8EX34EU / Creatinine; N91BDP6H0X / Choline
  •  go-up   go-down


68. Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW, Haugen BR: Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog; 2006 Aug;45(8):613-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to better understand basic mechanisms of tumor development and identify potential new biomarkers, we have performed difference gel electrophoresis (DIGE) and peptide mass fingerprinting on pooled protein extracts from patients with papillary thyroid carcinoma (PTC) compared with matched normal thyroid tissue.
  • We confirmed S100A6 as a potentially useful biomarker using immunohistochemical analysis (85% sensitivity and 69% specificity for distinguishing benign from malignant thyroid neoplasms).

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Mar;56(3):281-90 [11940037.001]
  • [Cites] Proteomics. 2002 Jun;2(6):706-12 [12112852.001]
  • [Cites] Oncogene. 2002 Aug 1;21(33):5056-68 [12140756.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1777-80 [12168868.001]
  • [Cites] Cancer. 1977 Jul;40(1):284-300 [880557.001]
  • [Cites] Endocrinologie. 1979 Oct-Dec;17(4):233-9 [392693.001]
  • [Cites] Anal Biochem. 1984 Apr;138(1):141-3 [6731838.001]
  • [Cites] J Biol Chem. 1991 Oct 25;266(30):20198-204 [1939080.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Dec;75(6):1398-400 [1464638.001]
  • [Cites] N Engl J Med. 1993 Feb 25;328(8):553-9 [8426623.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6027-31 [7954439.001]
  • [Cites] J Chromatogr B Biomed Appl. 1995 May 5;667(1):153-60 [7663678.001]
  • [Cites] Int J Cancer. 1996 May 16;66(4):420-6 [8635854.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3112-7 [8674069.001]
  • [Cites] Hum Pathol. 1996 Jul;27(7):633-6 [8698304.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3634-7 [8705997.001]
  • [Cites] Biochim Biophys Acta. 1996 Aug 23;1316(3):203-9 [8781539.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):325-32 [8903474.001]
  • [Cites] Electrophoresis. 1997 Oct;18(11):2071-7 [9420172.001]
  • [Cites] N Engl J Med. 1998 Jan 29;338(5):297-306 [9445411.001]
  • [Cites] Semin Surg Oncol. 1999 Jan-Feb;16(1):34-41 [9890738.001]
  • [Cites] Electrophoresis. 1998 Dec;19(18):3213-6 [9932817.001]
  • [Cites] Mol Endocrinol. 2005 Mar;19(3):683-97 [15528267.001]
  • [Cites] Histopathology. 2005 May;46(5):569-75 [15842639.001]
  • [Cites] Bioessays. 2002 Aug;24(8):749-57 [12210536.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):68-75 [12538453.001]
  • [Cites] Lancet. 2003 Feb 8;361(9356):501-11 [12583960.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1454-7 [12670889.001]
  • [Cites] J Proteome Res. 2003 Mar-Apr;2(2):199-205 [12716134.001]
  • [Cites] J Clin Pathol. 2003 Jun;56(6):401-5 [12783963.001]
  • [Cites] Proteomics. 2003 Jul;3(7):1162-71 [12872217.001]
  • [Cites] Thyroid. 2003 Jul;13(7):613-20 [12964965.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):994-1005 [14764826.001]
  • [Cites] Tumori. 2003 Sep-Oct;89(5):517-9 [14870775.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Proteomics. 2004 Mar;4(3):793-811 [14997500.001]
  • [Cites] FASEB J. 2004 Mar;18(3):560-1 [14715705.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2035-43 [15041723.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1600-5 [15083192.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1234-42 [15085203.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]
  • [Cites] Mol Cell Proteomics. 2004 Jun;3(6):531-3 [15075378.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4069-77 [15205313.001]
  • [Cites] Mult Scler. 2004 Jun;10(3):245-60 [15222687.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3214-23 [15240595.001]
  • [Cites] Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7 [15319714.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22 [15336958.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3531-9 [15337802.001]
  • [Cites] Proteomics. 2004 Sep;4(9):2776-88 [15352251.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Sep;89(9):4264-6 [15356019.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6586-97 [15475448.001]
  • [Cites] Mol Cell Proteomics. 2004 Oct;3(10):960-9 [15238602.001]
  • [Cites] Arch Pathol. 1967 Dec;84(6):601-14 [6054261.001]
  • [Cites] Cancer. 1971 Sep;28(3):763-74 [5096937.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Eur J Biochem. 2000 Oct;267(19):6067-73 [10998068.001]
  • [Cites] Adv Clin Path. 2000 Oct;4(4):155-8 [11436147.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4920-5 [11600563.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Apr;1(3):173-81 [11705003.001]
  • (PMID = 16788983.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100560; United States / NCI NIH HHS / CA / P30 CA046934; United States / NCI NIH HHS / CA / R01 CA100560; United States / NCI NIH HHS / CA / P30 CA46934-15; United States / NIDDK NIH HHS / DK / R01 DK054383; United States / NIDDK NIH HHS / DK / DK054383
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Neoplasm Proteins; 0 / S100 Proteins; 105504-00-5 / S100A6 protein, human
  • [Other-IDs] NLM/ NIHMS20526; NLM/ PMC1899163
  •  go-up   go-down


69. Zhang S, Gao F, Chen LS, Tang ZJ, Liang JL, Wu Q: [Clinical analysis of anorectal malignant melanoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Jul;8(4):309-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of anorectal malignant melanoma].
  • OBJECTIVE: To summarize the clinicopathological characteristics of primary anorectal malignant melanoma (AMM).
  • RESULTS: Anorectal malignant melanoma had a female predominance.
  • The average age was 56 years old and average course of disease was 5.8 months.
  • The onset of symptom was hematochezia, then anus prolapses.
  • 94.7% of patients had AMM within 5 cm from anus margin; the average tumor size was (3.3+/- 2.1) cm.
  • More than a half (54.5%) of the tumor was movable, 19.1% smooth surfaced, 6.6% soft textured.
  • Half of the patients were misdiagnosed,and over 50% of patients were misdiagnosed as benign disease.
  • Mile's operation was performed in most of patients (63%), while anal resection was performed in 30% of the patients.
  • CONCLUSIONS: Anorectal malignant melanoma is often misdiagnosed,surgical procedure is the first choice for patients with AMM.
  • [MeSH-major] Anus Neoplasms / pathology. Melanoma / pathology. Rectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167248.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


70. Chen R, Pan S, Duan X, Nelson BH, Sahota RA, de Rham S, Kozarek RA, McIntosh M, Brentnall TA: Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer; 2010 Jun 15;9:149
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia.
  • BACKGROUND: Pancreatic intraepithelial neoplasias (PanINs) are precursors of malignant pancreatic cancer, an ideal stage for early cancer detection.
  • An ELISA assay was developed to evaluate AGR2 levels in 51 pancreatic juice samples and 23 serum samples from patients with pancreatic cancer, pre-malignant lesions (including PanIN3, PanIN2, Intraductal Papillary Mucinous Neoplasms (IPMNs)) and benign disease controls (including chronic pancreatitis).
  • AGR2 levels in the pancreatic juice samples were found significantly elevated in patients with pre-malignant conditions (PanINs and IPMNs) as well as pancreatic cancer compared to control samples (p < or = 0.03).
  • By ROC analysis, the AGR2 ELISA achieved 67% sensitivity at 90% specificity in predicting PanIN3 juice samples from the benign disease controls.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Clin Sci (Lond). 2010 Jun;118(12):717-25 [20136634.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Pancreas. 1994 Nov;9(6):741-7 [7846018.001]
  • [Cites] Mech Dev. 1998 Mar;72(1-2):115-30 [9533957.001]
  • [Cites] Ann Intern Med. 1999 Aug 17;131(4):247-55 [10454945.001]
  • [Cites] Mol Cell Proteomics. 2004 Dec;3(12):1154-69 [15385600.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):523-33 [15684406.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6626-36 [16103885.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1208-17 [16424060.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1728-34 [16551856.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2066-9 [16609017.001]
  • [Cites] Histol Histopathol. 2007 Jul;22(7):703-8 [17455144.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):303-10 [17674958.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(3):293-300 [17457305.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Sep;23(5):508-14 [17762556.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Nov;5(10):1034-41 [18053427.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):492-7 [18199544.001]
  • [Cites] EMBO Rep. 2008 May;9(5):429-34 [18451766.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7811-8 [18829536.001]
  • [Cites] Cancer Detect Prev. 2008;32(3):236-50 [18801625.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] PLoS Med. 2009 Apr 7;6(4):e1000046 [19360088.001]
  • [Cites] Electrophoresis. 2009 Apr;30(7):1132-44 [19373808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):6950-5 [19359471.001]
  • [Cites] Histol Histopathol. 2009 Sep;24(9):1121-8 [19609859.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • (PMID = 20550709.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01DK081368; United States / NCI NIH HHS / CA / CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296-02; United States / NCI NIH HHS / CA / K07 CA116296; United States / NCI NIH HHS / CA / R01CA107209; United States / NCI NIH HHS / CA / K07CA116296; United States / NCI NIH HHS / CA / K25CA137222
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteins; EC 5.3.4.1 / AGR2 protein, human
  • [Other-IDs] NLM/ PMC2893103
  •  go-up   go-down


71. Christensen AF, Nyhuus B, Nielsen MB: Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer. Dis Colon Rectum; 2009 Mar;52(3):484-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer.
  • PURPOSE: This study was designed to evaluate the interobserver and intraobserver agreement of two-dimensional (2-D) and three-dimensional (3-D) anal endosonography for the detection of local recurrence anal carcinoma.
  • METHODS: Thirty-six patients were treated for anal carcinoma, and seven had recurrent disease.
  • The observers scored each examination according to the following scale regarding presence of local recurrence: 1 = no finding/benign findings; 2 = properly benign findings; 3 = suspicious findings/malignant findings.
  • CONCLUSIONS: Three-dimensional endosonography proved to have significantly better interobserver and intraobserver agreement than 2-D endosonography concerning detection of recurrent anal cancer.
  • [MeSH-major] Anus Neoplasms / ultrasonography. Endosonography. Neoplasm Recurrence, Local / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / ultrasonography. Female. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Observer Variation. Retrospective Studies

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333050.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. van de Luijtgaarden AC, Veth RP, Slootweg PJ, Wijers-Koster PM, Schultze Kool LJ, Bovee JV, van der Graaf WT: Metastatic potential of an aneurysmal bone cyst. Virchows Arch; 2009 Nov;455(5):455-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aneurysmal bone cysts (ABCs) are benign bone tumors consisting of blood-filled cavities lined by connective tissue septa.
  • Multiple cases of malignant transformation of ABC into (osteo)sarcoma have been described, as well as a number of cases of telangiectatic osteosarcoma which had been misdiagnosed as ABC.
  • Diagnosis was confirmed by the presence of a break in the USP6 gene, which is pathognomonic for ABC, in a pulmonary metastasis of our patient.
  • Sarcomatous transformation as an explanation for this behavior was ruled out by demonstrating diploid DNA content in both the pulmonary lesion and the primary tumor.
  • [MeSH-major] Bone Cysts, Aneurysmal / pathology. Bone Neoplasms / pathology. Neoplasms, Second Primary / pathology. Osteosarcoma / pathology. Proto-Oncogene Proteins / genetics. Ubiquitin Thiolesterase / genetics
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Bevacizumab. Carcinoma / complications. Cell Transformation, Neoplastic / pathology. Diabetes Mellitus, Type 2 / complications. Embolization, Therapeutic. Female. Humans. Hyperplasia. In Situ Hybridization, Fluorescence. Kidney Neoplasms / secondary. Lung Neoplasms / secondary. Middle Aged. Thyroid Gland / pathology. Uterine Neoplasms / complications